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ABSTRACT OF THE DISSERTATION 
PROTEIN-PROTEIN INTERACTIONS OF BACTERIAL TOPOISOMERASE I 
by 
Srikanth Banda 
Florida International University, 2017 
Miami, Florida 
Professor Yuk-Ching Tse-Dinh, Major Professor 
            Protein-protein interactions (PPIs) are essential features of cellular processes 
including DNA replication, transcription, translation, recombination, and repair. In my 
study, the protein interactions of bacterial DNA topoisomerase I, an essential enzyme, were 
investigated. The topoisomerase I in bacteria relaxes excess negative supercoiling on DNA, 
and maintains genomic stability. Investigating the PPI network of DNA topoisomerase I 
can further our understanding of the various functional roles of this enzyme. My study is 
focused on topoisomerase I of Escherichia coli and Mycobacterium smegmatis. Firstly, we 
have explored the biochemical mechanisms for an interaction between RNA Polymerase, 
and topoisomerase I in E. coli. Molecular docking, and molecular dynamic simulations 
have predicted that the interactions are mediated through electrostatic, and hydrogen 
bonding. The predicted Lysine residues (K627, K664) of topoisomerase I that are involved 
in the electrostatic interactions were mutated to Alanine, and its effect on the binding 
efficiency with RNA polymerase was reported. In a separate study, PPI partners of 
topoisomerase I in mycobacteria were identified. Knowledge gained from the study can 
provide valuable insights into the physiological functions of a validated drug target, DNA 
topoisomerase I, in pathogenic mycobacteria. Co-immunoprecipitation, and pull-down 
 vii 
assays were coupled to mass spectrometry for identification of the protein partners of 
mycobacterial topoisomerase I. The study has identified RNA polymerase, and putative 
helicases (DEAD/DEAH BOX helicases) as potential protein partners of mycobacterial 
topoisomerase I. My results indicated that the tail region of the CTD-topoisomerase I was 
required for direct physical interaction with the RNAP beta’ subunit. My studies have also 
verified the physiological relevance of the topoisomerase I - RNA polymerase interactions 
for survival under antibiotic, and oxidative stress. Lastly, I report a direct physical 
interaction between E. coli topoisomerase I and RecA by pull-down assays. Previous 
studies have shown that RecA, a DNA repair protein, can stimulate the relaxation activity 
of E. coli topoisomerase I. Our new results showed that the stimulatory effect can be 
attributed to the physical interaction of topoisomerase I with RecA.  
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INTRODUCTION 
 
 
A. TOPOISOMERASES AND GENOME STABILITY 
 
The DNA topoisomerases have been termed “the magicians of the DNA world” as 
they resolve all the topological problems of DNA (Wang, 2002). Ever since the discovery 
of topoisomerases in Escherichia coli by James Wang, considerable research has been 
conducted to study the implications of these enzymes on the essential cellular processes. 
James. C. Wang treated covalently closed circular DNA duplexes containing negative 
supercoils with a purified E. coli protein ω and observed a partial loss of the supercoiling 
(Wang, 1971). He also observed that the protein is intrinsically carrying out the functions 
of endonucleases (nicking the DNA) and DNA ligases (Resealing the DNA). The protein, 
ω, is now referred to as topoisomerase I. Later, James Champoux discovered that a mouse 
nuclear extract could remove the supercoils from closed circular polyoma virus DNA by 
nicking and sealing activities (Champoux & Dulbecco, 1972), hinting at the possibility of 
the existence of enzymes in eukaryotic cells identical to those of the prokaryotic 
topoisomerase I.  The common ground for the enzymes/proteins discovered by Wang and 
Champoux was their ability to relax the supercoiled DNA (Champoux, 2001; Wang, 2002). 
However, it was postulated that the mechanism of relaxing the supercoiled DNA by the 
prokaryotic topoisomerase I is different from its eukaryotic counter-part (Maxwell & 
Gellert, 1986). The prokaryotic enzyme discovered by Wang is now categorized as a type 
IA topoisomerase, and the eukaryotic enzyme discovered by Champoux is classified under 
type IB.  Martin Gellert and co-workers discovered DNA gyrase, a prokaryotic DNA 
topoisomerase II that could introduce supercoils, during a search for the co-factors of the 
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host that support site-specific recombination by bacteriophage λ (Gellert et al., 1976). 
Studies on archaea, a third domain of life, apart from eukaryotes and prokaryotes, have led 
to the discovery of reverse gyrase (Kikuchi & Asai, 1984), DNA topoisomerase V 
(Slesarev, 1993) and DNA topoisomerase VI (Bergerat et al., 1997). Reverse gyrase, a 
unique enzyme found only in the thermophiles have been reported to introduce positive 
supercoils to a relaxed DNA molecule (Declais et al., 2001). The currently discovered 
topoisomerases fall in to two categories: type I and type II (Table I. T1). The type I 
topoisomerases transiently cleave a single strand of the DNA in an ATP-independent 
manner, whereas the type II topoisomerases transiently break both strands of the DNA in 
an ATP-dependent manner.  
The type I topoisomerases were further subdivided in to type IA, and IB based on 
the polarity of strand cleavage. The activities of type I topoisomerases are depicted in figure 
I. 2. Type IA enzymes form a transient 5’-phosphotyrosine covalent complex and releases 
a free 3’-OH end whereas the type IB forms a 3’-phosphotyrosine covalent complex and 
produces a free 5’-OH end. Another differentiation is that the type IA promotes the passage 
of the intact strand through the broken strand (strand passage), whereas the type IB allows 
the broken strand to freely rotate around the intact strand. Type IA topoisomerases are 
composed of two domains: a conserved core domain that is involved in the trans-
esterification reactions, and a carboxyl-terminal domain highly variable in size and 
sequence (Figure I. 1) (Viard et al., 2007). Type IA topoisomerases are present in bacteria 
(topoisomerase I, III), archaea (reverse gyrase) and eukarya (topoisomerase IIIa and 
topoisomerase IIIb). Type IB topoisomerases, DNA swivelases, fundamentally differ in 
the structure and mechanism from type IA topoisomerases (Redinbo et al., 1998). Type IB 
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topoisomerases are ubiquitous in eukaryotes, with some homologues scattered among a 
few viruses and bacteria (Krogh & Shuman, 2002). The type IB enzymes have a 
preferential binding for positively or negatively supercoiled DNA substrates rather than the 
relaxed substrates (Madden et al., 1995; Frohlich et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I. 1. Domain organization of type IA topoisomerases (Viard et al., 2007). 
(a)Sequence alignment of type IA topoisomerases across different organisms. The 
conserved sequences are represented by foreground gray boxes. Orange boxes: Putative 
tetracysteine zinc finger motifs. Crossed orange boxes: Putative tetracysteine zinc finger 
motifs with one or two histidines instead of cysteines. The domains are color coded: 
domain I (yellow), domain II (green), domain III (red), domain IV (blue), domain V 
(purple). Refer to the abbreviations section for the description of enzyme abbreviations.  
(b) A general schematic of an open and closed structure of type IA topoisomerases. The 
active site tyrosine (Y, red colored) is in domain III. 
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The structural and sequential differences between type IA and type IB have 
confirmed the independent origins of these enzymes (Forterre et al., 2007). Most of the 
type I topoisomerases exist as monomeric units, formed by a single topoisomerase domain. 
However, reverse gyrase and Topoisomerase V are exceptions, as they have a 
topoisomerase domain bound to a helicase-like domain in the case of reverse gyrase and 
DNA repair-like domain in the case of Topoisomerase V. Classified under type IC family, 
Topoisomerase V has a mechanism of action that is similar to that of type IB enzymes. 
However, topoisomerase V is distinct in having no sequence or structural similarities with 
other topoisomerases (Baker et al., 2009). Strikingly, topoisomerase V is a bifunctional 
enzyme, carrying out the functions of DNA relaxation through its N-terminal (Slesarev et 
al., 1993) and DNA repair via its C-terminal (Belova et al., 2001).  
E. coli topoisomerase I, a type IA topoisomerase, can only relax negative 
supercoils. Whereas the eukaryotic topoisomerase I, a type IB topoisomerase, can relax 
both negative and positive supercoils (Champoux & Dulbecco, 1972; Pommier 2010). The 
DNA topoisomerase I or topoisomerase III deletion mutants of E. coli are viable, 
suggesting an apparent non-essentiality of these enzymes in E. coli (Stupina & Wang., 
2005). However, each organism must have at least one type IA topoisomerase activity to 
be viable. The potential for bacterial topoisomerase I to form a stable complex with DNA, 
leading to the SOS response and eventual cell death has made this enzyme a potential 
antibacterial drug target (Cheng et al., 2005). Unlike in E. coli, the topoisomerase I of M. 
tuberculosis and M. smegmatis was reported to be indispensable because there is no other 
type IA topoisomerase present in mycobacteria (Ahmed et al., 2014, 2015). Currently, there 
are no commercially available antibacterial agents targeting bacterial topoisomerase I. 
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Efforts to identify and develop novel drugs against bacterial topoisomerase I are on the 
rise. Human topoisomerase I, on the other hand, is a well-established target for cancer 
chemotherapy. Camptothecin and its analogs are being widely used clinically to target the 
human topoisomerase I (Wall & Wani., 1995).  
 
Figure I. 2. Type I topoisomerases as modulators of DNA Topology (Bush et al., 2015). 
Type I topoisomerases can catalyze the relaxation of a supercoiled DNA. Reverse gyrase 
can introduce positive supercoils in the DNA. Knotting/unknotting, 
catenation/decatenation, and duplex formation of DNA are also catalyzed by the type I 
topoisomerases. 
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Type II topoisomerases have been reported in all proliferating cells and are 
essential for the survival of all species (Watt & Hickson, 1994; Wang, 1996). Type II 
topoisomerases in bacteria are represented by DNA gyrase and topoisomerase IV. In 
eukaryotes, type II topoisomerases are represented by two closely related isoforms, 
topoisomerase IIa and topoisomerase IIb. The isoforms are encoded by different genes, 
although displaying a high degree (70%) of amino acid sequence identity (Champoux, 
2001; McClendon & Osheroff, 2007).  Topoisomerase IIa is indispensable as it is essential 
for the survival of actively growing cells. Topoisomerase IIb, although dispensable the 
cellular level, is required for the neural development in mice (Yang et al., 2000). Type II 
topoisomerases, in contrast to type I topoisomerases, are multimeric enzymes (Figure I. 3). 
Each monomer of the enzyme has an ATP binding domain, and an active site responsible 
for the cleavage-religation of a single strand of DNA.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
      Figure I. 3. Domain structures of type II topoisomerases (Aldred et al., 2014) 
  
 7 
Chromosomal segregation after DNA replication, and before cell division requires 
topoisomerase II activity (Hartsuiker et al., 1998). Therefore, topoisomerase II is 
indispensable for cell survival, and can serve as a potential drug target in cancer and 
antibiotic therapies. The activities of type II topoisomerases are depicted in figure I. 4. The 
cellular levels of topoisomerases have a direct relation with the growth rates, and mitotic 
failure is reported when the cellular levels drop below the threshold (Nitiss, 1998). 
 
 
 
Figure I. 4. Type II topoisomerases as modulators of DNA Topology (Bush et al., 
2015). Type II topoisomerases can catalyze the relaxation of a supercoiled DNA, apart 
from catenation/decatenation, and knotting/unknotting of DNA. Gyrase can also introduce 
supercoils into DNA. Here, only the relaxation of negatively supercoiled DNA by type II 
topoisomerases is shown. However, it should be noted that all the known type II 
topoisomerases can also relax positively supercoiled DNA. 
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Table I. T1. Classification of Topoisomerases 
 
Subfamily 
                    
                  Representative members 
 
Mechanism of   Action 
 
ATP dependence 
 
          IA 
• Bacterial DNA topoisomerase I, III 
Yeast DNA topoisomerase III 
• Drosophila melanogaster DNA topoisomerases IIIα, IIIβ 
• Mammalian DNA topoisomerases IIIα, IIIβ 
• Reverse Gyrase (Thermophilic Archaea) 
 
 
       Strand passage 
 
 
         No 
(Reverse Gyrase is 
an exception) 
 
         IB 
• Eukaryotic DNA topoisomerase I 
• Mammalian mitochondrial DNA topoisomerase I 
• Pox virus topoisomerase 
 
 
          Swivel 
 
 
          No 
 IC Methanopyrus kandleri DNA topoisomerase V            Swivel           No 
        IIA 
• Bacterial gyrase, DNA topoisomerase IV 
• Phage T4 DNA topoisomerase. 
• Yeast DNA topoisomerase II 
• Drosophila DNA topoisomerase II 
• Mammalian DNA topoisomerases IIα, IIβ 
 
 
     Strand passage 
 
 
         Yes 
       IIB 
 
• Sulfolobus shibatae DNA topoisomerase VI  
 
 
      Strand passage 
 
        Yes 
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B. TOPOISOMERASES AS THERAPEUTIC TARGETS 
Topoisomerases have garnered attention of the scientific community for their 
potential as chemotherapeutic and antibiotic drug targets. Topoisomerases are the 
caretakers of the genome. Multitudes of topoisomerases coordinate the essential processes 
such as replication, transcription, recombination, and repair (Figure I.5). Topoisomerases 
address the supercoiling problems by cleaving (single or double strand), and religating the 
cleaved DNA. During the cleavage process, the enzyme and DNA are linked as covalent 
complexes momentarily. The covalent complex serves as a potential drug target (Pommier 
et al., 2010).  
 
 
 
 
  
 
 
 
 
 
Figure I. 5. Coordination of topoisomerases in the DNA replication, and transcription 
processes (Vos et al., 2011)  
 
The tyrosine of the enzyme’s active site attacks the phosphorous of DNA, forming 
a phosphotyrosine covalent complex and thereby, breaking the phospho-diester back bone 
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of a single strand of DNA. A strand passage (type IA, IIA, IIB) or swivel mechanism (type 
IB), depending on the enzyme’s subfamily (Table I. T1), will precede the religation step 
(Figure I.6). A second trans-esterification reaction allows the religation of the DNA strand. 
However, in the case of second trans-esterification, the oxygen of the DNA hydroxyl group 
(generated in the cleavage reaction) attacks the phosphorous of the phosphotyrosine link, 
and breaks the covalent bond between the enzyme and DNA (Wang, 2002).  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.6. Covalent cleavage complex via transesterification reaction (Wang, 2002). 
The reaction represented here is relevant for the transesterification reactions mediated by 
the type IA, and type II topoisomerases. A reversal of the reaction causes the religation of 
the cleaved DNA strand. Type IB topoisomerase reactions (not shown here) are mediated 
via complex formation of the active site tyrosine with the 3’-phosphoryl group.  
 
Insights into the DNA relaxation mechanisms of topoisomerases have paved the 
way for design and identification of drugs that target either the covalent DNA-enzyme 
complexes or the catalytic activity of the enzyme (Table I.T2). The drugs have been 
categorized into two different classes, “topoisomerase poison inhibitors or catalytic 
inhibitors”, depending on their mode of action. Topoisomerase poison inhibitors essentially 
convert the enzymes into cellular toxins by increasing the concentrations of enzyme-linked 
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DNA breaks in treated cells and hence, the name topoisomerase poisons (Pommier, 2013). 
The catalytic inhibitors of topoisomerases, on the other hand, block the overall activity of 
the topoisomerase, causing the enzyme to lose its functionality (Fortune et al., 2000). 
Catalytic inhibitors are only effective if the cellular activity of the enzymes is nearly 
completely inhibited, whereas poison inhibitors can trigger cell death by trapping a small 
subset of topoisomerase mediated covalent complexes (Aedo & Tse-Dinh, 2012).  
 
Figure I. 7. Repair pathways for the removal of topoisomerase-DNA complexes  
(Pommier, 2013) 
 
Eukaryotic topoisomerase I or topoisomerase II serve as targets for drugs used in 
cancer therapy. For instance, Camptothecin, a plant alkaloid with a potential for anti-cancer 
activity has topoisomerase I as its only known target. Camptothecin and its derivatives 
(Irinotecan, Topotecan), reportedly trap the covalent complex of DNA and topoisomerase 
I, thereby inhibiting the religation step (Pommier et al., 2005). As the cleavage complexes 
are trapped by Camptothecin, DNA repair pathways (Figure I.7) may intervene. Hence, a 
combination therapy would be a preferred alternative to using Camptothecin alone. 
Camptothecin in combination with drugs that target the topoisomerase I induced DNA 
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damage repair pathways are gaining popularity over the use of the Camptothecin 
derivatives alone (Zhang et al., 2011; Pommier, 2013). Like topoisomerase I-mediated cell 
killing, drugs targeting the topoisomerase II activities have also been discovered. 
Topoisomerase II, essentially, creates a double strand break in the cellular DNA and these 
breaks as such do not pose a threat to the genomic stability under normal physiological 
conditions, as the breaks are short lived (Wang, 1996). However, if the covalent complexes 
of topoisomerase II and DNA are trapped, the concentrations of covalent complexes rise 
significantly, and apoptotic pathways are triggered. Genomic aberrations can also arise 
from the insertions, deletions and illegitimate recombination as a result of the 
topoisomerase-mediated DNA breaks (Fortune et al., 2000). 
 
 
 
 
 
 
 
 
Figure I. 8. Formation of a Drug-DNA-Topoisomerase II ternary complex  
(Fortune et al., 2000) 
 
Eukaryotic topoisomerase II is a potential target for the most successful anticancer 
drugs used clinically in the treatment of human malignancies (Pommier, 1997). The drugs 
are structurally diverse, but share a common feature in their aromatic core interacting with 
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DNA in the enzyme-drug-DNA ternary complex (Figure I.8) (MacDonald et al., 1991). 
Identification of the anticancer drug interaction domains of topoisomerase II from three-
dimensional structure of the drug-stabilized ternary cleavage complex can provide a 
breakthrough in development of chemotherapeutic drugs. A crystal structure of the human 
topoisomerase II b isoform (core) in complex with the DNA, and an anticancer drug 
etoposide has been reported (Figure I.9) (Wu et al., 2011). The crystal structure information 
has provided insights into the binding modes of etoposide, and has also opened avenues 
for future drug development. 
 
 
Figure I.9. Crystal structure of human topoisomerase II b (core) in complex with 
DNA, and Etoposide (Wu et al., 2011). (A) Linear domain organization of human 
topoisomerase II b. The DNA binding and cleavage core was used in the study. (B) The 
palindromic DNA substrate used for crystallization studies. The arrows are indicative of 
the cleavage sites. (C) Orthogonal views of the crystal. 
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Prokaryotic topoisomerase II enzymes, DNA gyrase and topoisomerase IV, are 
targets for two classes of antibiotic drugs: quinolones and coumarins. These drugs are 
effective against pathogens causing tuberculosis, pneumonia and malaria. 
Fluoroquinolones (Moxifloxacin, Gatifloxacin, Oflaxacin, Levofloxacin etc.,) are proven 
to be the most successful agents against bacterial pathogens including tuberculosis (TB). 
Development of fluoroquinolone resistance has been a concern, especially when it is 
administered as monotherapy (Ginsberg et al., 2003). There is an urgent need for the 
development of drugs treating the multidrug-resistant and extensively drug-resistant 
tuberculosis (Gunther, 2014). 
A three-drug regimen, moxifloxacin in combination with pretomanid and 
pyrazinamide, was reported to be effective against TB and MDR-TB compared to the 
currently used regimen (Dawson & Diacon, 2013). Fluoroquinolones are involved in 
forming complexes with gyrase and DNA, resulting in the poisoning of M. tuberculosis. 
The development of crystal structures of quinolones in complex with gyrase-DNA, and 
topoisomerase IV-DNA has advanced our understanding of the quinolone resistance 
mutations. Structural information of these complexes can provide valuable insights for the 
development of new quinolone agents. The crystal structure has revealed the importance 
of water shell of an associated magnesium ion in forming a bridge between fluoroquinolone 
and gyrase (Figure I.10) (Blower et al., 2016). Quinolones also have a secondary target, 
topoisomerase IV, in some bacteria. In Staphylococcus aureus, quinolones primarily target 
topoisomerase IV. The crystal structure of Acinetobacter baumannii topoisomerase IV 
complexed with DNA and moxifloxacin shows the wedge-shaped quinolone stacking 
between the DNA base pairs at the cleavage site. The quinolone stacked in the DNA can 
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bind the conserved residues of topoisomerase IV DNA cleavage domain via chelation of 
noncatalytic magnesium ion (Figure I.11) (Wohlkonig et al., 2010). The aromatic rings of 
quinolone are involved in DNA base stacking at the cleavage site, and at the same time the 
quinolone is interacting with the residues of the both subunits of the enzyme for creating a 
cleavage complex, which has been a common theme among the complexes crystalized thus 
far. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.10. Crystal structure of M. tuberculosis GyrBA core in complex with DNA 
and moxifloxacin (Blower et al., 2016). (A) The GyrBA fusion comprises of amino acids 
426-675 of GyrB, and amino acids 2-500 of GyrA. The fused protein is shown in two 
shades of pink and blue. The DNA is represented in orange. Magnesium ions are shown as 
yellow spheres, and Moxifloxacin is shown by green spheres. (B-D) Orthogonal views of 
the complex. 
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The overuse of quinolones has resulted in a rise in the quinolone-resistant bacterial 
strains. Target-mediated resistance, plasmid-mediated resistance, or chromosome-
mediated resistance are the possible mechanisms for development of quinolone resistance 
(Aldred et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.11. Crystal structure of Acinetobacter baumannii topoisomerase IV in 
complex with moxifloxacin and DNA (Wohlkonig et al., 2010). (a) C-terminal of ParE 
region is fused with the N-terminal of ParC. (b) The complex of ParE28-ParC58 with DNA 
(green), Moxifloxacin (yellow carbons) and magnesium ions (orange spheres).  
 
The development of fluoroquinolone-resistant bacteria has been a cause of major 
public health concern. Hence, there is a need for identification of novel inhibitors or novel 
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drug targets. Bacterial topoisomerase I, an essential enzyme in pathogens like M. 
tuberculosis, is being pursued for its potential as a novel drug target (Tse-Dinh 2007, 2009, 
2015; Nagaraja, 2017). Bacterial topoisomerases I, a type IA topoisomerase, can form a 
transient covalent complex during the DNA cleavage-religation reaction of DNA 
relaxation process. The potential for topoisomerase I mediated accumulation of covalent 
complexes in the initiation of cell death pathway was studied by random mutagenesis of 
recombinant topoisomerase I. The mutations on topoisomerase I that can induce the SOS 
DNA repair system in response to the DNA damage were identified (Cheng et al., 2005; 
Tse-Dinh, 2009). The studies have highlighted the importance of divalent Mg+2 in the DNA 
rejoining activity of E. coli topoisomerase I. The DxD motif in the TOPRIM domain of E. 
coli topoisomerase I is involved in binding with the divalent Mg+2. According to the 
studies, the D111N mutation of the first aspartate of DxD motif was extremely lethal. The 
absence of a negatively charged carboxylate side chain of aspartate can be attributed to the 
loss of Mg+2 binding (Cheng et al., 2009). The lack of Mg+2 bound to topoisomerase I can 
inhibit the DNA rejoining after cleavage which can initiate the cell death. Based on these 
studies, it is ideal to develop small molecules that can serve as poison inhibitors by 
interfering with the Mg+2 binding at the site of topoisomerase I (Tse-Dinh, 2009). It should 
be noted that a strictly conserved arginine residue in the proximity of the active site is also 
required for the rejoining activity (Narula et al., 2011). Recently identified bacterial 
topoisomerases I inhibitors include some phenanthrene compounds (Cheng et al., 2007; 
Ferrandiz et al., 2014), and Bisbenzimidazoles (Nimesh et al., 2014; Bansal et al., 2010; 
Ranjan et al., 2014). 
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Table I. T2. Inhibitors of topoisomerases 
Drug Target Application 
Quinolones 
(e.g. Nalidixic acid, and 
Ciprofloxacin) 
DNA gyrase, and 
topoisomerase IV Antibacterial  
Coumarins 
(e.g. Novobiocin, and 
Coumermycin A1) 
DNA gyrase, and 
topoisomerase IV Antibacterial  
Camptothecin 
(e.g. Topotecan) Human topoisomerase I Anticancer 
Acridines 
(e.g. Amsacrine (mAMSA)) Human topoisomerase II Anticancer 
Ellipticines 
(e.g. 2-methyl-9-hydroxy-
ellipticinium acetate) 
Human topoisomerase II Anticancer 
Epipodophyllotoxins 
(e.g. Teniposide) Human topoisomerase II	 Anticancer	
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C. PROTEIN-PROTEIN INTERACTIONS;  
CROSS-TALK BETWEEN PROTEINS 
 
An interplay between proteins, protein-protein interactions (PPIs), is required for 
virtually every cellular process; be it DNA replication, transcription, translation, splicing, 
secretion, cell cycle control, signal transduction or intermediary metabolism (Phizicky et 
al., 1995). PPIs are generally transient, and the proteins involved in transient interactions 
can exist independently. A trigger (for example, a post-translational modification) can 
initiate interactions between proteins to carry out the essential cellular processes (Perkins 
et al., 2010). A closer look at the protein-protein interaction network can give us an insight 
into the multiple roles of individual proteins. Most of the proteins have a unique activity, 
and the coordination between proteins with unique activities is required for carrying out 
essential cellular processes. Some proteins could be in a dormant state, until they bind to a 
regulatory protein partner. Specific domains in the protein will help in the interactions with 
other proteins, and the binding phenomena could be explained by the hydrophobic bonding, 
van der Waals forces, formation of a salt bridge (Xu et al., 1997). The strength of binding 
is sometimes proportional to the size or nature of the binding domain. The interactions with 
binding partners could be strong or weak, transient or stable (Golemis, 2002).   
Protein-protein interactions can result in altered enzyme kinetics as a result of 
allosteric effects. The protein interactions could up-regulate or down-regulate the activities 
of proteins involved, implying an inter-dependence of the binding partners. Most of the 
protein-protein interactions are transient; meaning the proteins part ways, after the desired 
function is served. The protein oligomers formed by transient interactions can be weak, or 
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strong in nature (Figure I.12). Weak transient interactions can result in a multitude of 
dynamic oligomeric states in vivo, whereas a change in the quaternary states of the stronger 
transient complexes can be triggered by ligand binding. 
 
 
 
 
 
 
 
 
Figure I. 12. Different types of PPIs based on their binding affinities 
(Perkins et al., 2010) 
 
It is a challenge to identify the transient PPIs, as the prerequisite for such a study is 
the identification of the conditions favoring the transient interactions. Some of the widely-
used methods for the identification of the PPIs include protein affinity chromatography 
(pull-down assays), affinity blotting, co-immunoprecipitation (Co-IP), Yeast 2-hybrid 
system, and far western blot analysis (Edmondson et al., 2001). Pull-down assays, and Co-
IP assays can detect strong/stable protein interactions. The coupling of mass spectrometry 
with the pull-down and Co-IP assays is a powerful tool in the identification of protein 
complexes (Bymora et al., 2004; Free et al., 2009). Transient/weak interactions can be 
identified by crosslinking interaction analysis (Yakovlev, 2009), and label transfer protein 
interaction analysis (Minami et al., 2000). The binding kinetics can be studied by 
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approaches like surface plasmon resonance (Jonsson et al., 1991), and isothermal 
calorimetry (Jayanthi et al., 2015). Computational methods to predict the protein-protein 
interaction networks have gained momentum. However, it is essential to validate the 
predicted protein-protein interactions through experiments. A commonly used tool, 
STRING, integrates the known (experimental) and predicted interaction network of protein 
for a more comprehensive viewing of the protein-protein interaction network (Figure I.13) 
(Von et al., 2005).  The STRING interactions are mapped based on the experimental data, 
curated databases (text mining), co-expression, protein homology, gene neighborhood, 
gene co-occurrence, and gene fusion. 
 
 
 
 
 
 
 
 
Figure I.13. Results from a STRING search of topoisomerase I (M. tuberculosis 
H37Rv); The protein interaction map of topoisomerase I (topA, red node) is obtained from 
the STRING search. The search also scores the individual interactions for a measure of 
confidence. The scores revealed a medium to high confidence in the interactions predicted 
for topA. (The scores are not shown here) (STRING version 10.5). 
 
Literature has provided evidence of the physical and functional interactions of 
topoisomerases with its protein partners. Identification of the protein partners of 
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topoisomerases can give us a valuable insight into the workings of these enzymes. For 
instance, sporulation and chromosome segregation in Streptomyces coelicolor, is only 
made possible by the recruitment of the Topoisomerase I (TopA) to ParB complexes on 
DNA. TopA and ParB, in combination, are required for sporulation and it was observed 
that the depletion of TopA in S. coelicolor has inhibited sporulation (Szafran et al., 2013).  
Human ADP ribosylation factor (ARF) is a recently discovered binding partner of 
Topoisomerase I, and is a critical component of the cellular reactions that require 
Topoisomerase I (Karayan et al., 2001). Interactions between RNA recognition motif 
(RRM) proteins and the cap region of the human topoisomerase I have proved to be critical 
for the kinase reactions catalyzed by topoisomerase I (Trzcinska-Daneluti et al., 2007). The 
relaxation activity of the topoisomerase I is inhibited by the binding of the splicing protein, 
SF2/ASF to the cap region (Amino acids: 215-433) of the topoisomerase I. The cap region 
of topoisomerase I is attracted to the two closely spaced RRM domains (Amino acids: 1-
94) on the SF2/ASF proteins (Kowalska-Loth et al., 2005; Trzcinska-Daneluti et al., 2007). 
Proteomic analysis of protein partners of human topoisomerase I by Co-
immunoprecipitation and affinity chromatography coupled with mass spectrometry had 
suggested that the N-terminal domain and the cap region of the topoisomerase I have a 
greater affinity for the proteins in nuclear extracts of HeLa cells. It is important to note that 
the majority of proteins with an affinity for the cap region of human topoisomerase I 
enclose two closely spaced RRM domains (Czubaty et al., 2005). Topoisomerase I 
relaxation activity is enhanced by interactions with ARF (Karayan et al., 2001), CK2, 
HMG, p53, PARP-1, PSF/P54nrp and Werner protein. In contrast, poly [ADP-ribosylated] 
PARP-1 and Tax HTLV-1 binding can inhibit the relaxation activity of topoisomerase I 
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(Czubaty et al., 2005). Binding assays (in vitro), and co-immunoprecipitation assays (in 
vivo) have provided proof of the specific interactions between Coprinus cinerus DNA 
topoisomerase II (CcTopII) and a meiosis-specific RecA-like protein, Lim15/Dmc1. The 
Lim15 interaction can potentially activate the in vitro catenation/relaxation activity of 
CcTopII, and CcTopII down regulates the CcLim15-dependent strand passage activity 
(Iwabata et al., 2005).    
All type IA topoisomerases modify DNA topology by an “enzyme-bridged strand 
passage mechanism” (Brown et al., 1979,1981). Sequence analysis has indicated that all 
the type IA topoisomerases are composed of a core, with conserved motifs and an active 
site (Berger, 1998; Champoux, 2001; Corbett et al., 2004), and a carboxy-terminal region, 
highly variable in size and sequence, containing a variable number of Zn+2 ribbon motifs 
ranging between 1 and 5 (Tse-Dinh et al., 1988; Bhaduri et al., 1998; Serre et al., 2003; 
and Bouthier et al., 1998). The C-terminal domains of type IA topoisomerase have been 
implicated in protein interactions that define the physiological activity of a topoisomerase 
(Figure I.14) (Viard et al., 2007). In humans, type IA topoisomerases have two 
representatives: Topoisomerase IIIα (TopIIIα) and Topoisomerase IIIβ (TopIIIβ) (Wang, 
2002).  The structural gene of TopIIIα is located on chromosome 17p11.2-12 (Hanai et al., 
1996) and the gene for TopIIIβ, a variant of TopIIIα is mapped within Ig lambda locus on 
chromosome 22q11-12 (Kawasaki et al., 1997). The existence of two different enzymes 
within the eukaryotic type IA topoisomerase sub-family could be justified by their 
functional differences through association with different helicases (Li et al., 1998). 
Experiments have been conducted to test the significance of these enzymes by targeted 
gene-disruption experiments in mice. The inactivation of TopIIIα in mice resulted in 
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embryonic lethality shortly after implantation (Li et al., 1998). A similar disruption of the 
TopIIIβ gene had no apparent effect on the embryo, but a reduction in the fertility 
accompanied by aneuploidy and reduced life span was observed (Kwan et al., 2001; Kwan 
et al., 2003). According to recent reports, deletion of TopIIIβ can contribute to 
neurodevelopmental disorders (Stoll et al., 2013), cognitive impairment, and facial 
dysmorphism (Kaufman et al., 2016).  TopIIIβ is a RNA topoisomerase that has been linked 
to schizophrenia and autism. The physical and functional association of human TopIIIβ 
with fragile X mental retardation protein (FMRP) is required for the regulation of the 
translation of mRNAs that are essential for the neuronal functions. Mutation in the FMRP 
can abolish the interaction with TopIIIβ, and can contribute to the development of neuronal 
disorders (Xu et al., 2013).  
 
 
 
 
 
 
 
 
Figure I.14. Schematic structures of known toposomes with their in vivo roles 
(Viard et al., 2007) 
 
The determinants of Bloom’s syndrome and Werner’s syndrome, the BLM and 
WRN genes respectively, encode for proteins resembling budding yeast SGS1 gene 
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product (Ellis et al., 1995, Yu et al., 1996), a DNA helicase that interacts physically and 
functionally with topoisomerase III (Gangloff et al., 1994 and Lu et al., 1996). Bloom’s 
syndrome, and Werner’s syndrome are associated with high incidence of cancers (Ellis et 
al., 1995, Yu et al., 1996). TopIIIα is recruited by the helicase BLM to resolve the in vivo 
non-canonical DNA structures (Double holliday junctions, D-loops, G-quadruplexes) (Wu 
et al., 2003). In Bloom syndrome patients, BLM helicase is mutated and fails to recruit 
TopIIIα, thereby increasing the sister chromatid exchanges in Bloom syndrome cells. 
Bloom syndrome patients are often diagnosed with cancer in their mid-twenties (German, 
1997). Gaining an understanding of the factors favoring or inhibiting the protein-protein 
interactions could be a huge advance in our understanding of the disease, and therapy. 
A paradigm shift is happening in the field of topoisomerases. The focus has been 
shifted from understanding the role of topoisomerases as independent units to the 
complexes they form with other proteins.  The in vivo role of a topoisomerase is defined 
by the protein partner it binds, rather than being encoded in its sequence or structure (Viard 
et al., 2007).  The term “toposome” has been coined for the protein complexes formed with 
the C-terminal domains of topoisomerase (Borowiec, 2004; Lee et al., 2004). There is 
increasing evidence surfacing to support the view that toposomes, and not independent 
units of topoisomerases, are involved in the physiological functions (Viard et al., 2007). 
Bacterial topoisomerase I, the subject of my research, belongs to the type IA subfamily. It 
should be noted that my research is aimed at the study of protein-protein interactions of 
topoisomerase I from Escherichia coli, Mycobacterium smegmatis, and Mycobacterium 
tuberculosis.   
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D. BACTERIAL TOPOISOMERASE I 
 
Bacterial topoisomerase I, a type IA topoisomerase of bacteria, can relax negatively 
supercoiled DNA through an enzyme-bridged strand passage mechanism (Figure I.15). The 
enzyme can form a transient 5’ covalent intermediate during the relaxation process. The 
bacterial topoisomerase I does not require an external source of energy, but requires a 
divalent cation for its activity (Baker et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 Figure I.15. Proposed enzyme bridged strand passage mechanism of relaxation by 
bacterial topoisomerase I (Viard et al., 2007). Step 1: Active site, tyrosine, binds to the 
substrate; Step 2: Cleavage of the substrate; Step 3: A change in Conformation of the 
enzyme, resulting in an opening of the gate. Step 4: Transfer of the unbound strand, and 
gate closure; Step 5: Resealing of the nicked substrate (Religation); Step 6: Change in the 
conformation of the enzyme, favoring the release of the relaxed substrate; Step 7: Release 
of the relaxed substrate, and return of the enzyme to its original conformation. 
 
Across bacteria, the type I topoisomerases, are similar in their structure, sequence, 
and mechanism of action. Although the N-terminal domains D1-D4 of topoisomerase I 
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share a high level of sequence homology, the C-terminal domains are highly variable in its 
size and sequence. It is believed that the C-terminal domains have a significant role in the 
DNA or protein interactions (Zhang et al., 1994; Beran-Steed et al., 1989). Bacterial 
topoisomerase I is present in all bacteria. However, bacterial topoisomerase III, another 
representative of the type IA topoisomerase family, is present only among some of the 
bacterial species. For instance, M. tuberculosis has only one representative of the type IA 
topoisomerase in the form of topoisomerase I. However, topoisomerase I and 
topoisomerase III are both present in E. coli. Studies have revealed the indispensability of 
the topoisomerase I in M. tuberculosis, validating its potential as a drug target in this 
pathogen (Godbole et al., 2015; Nagaraja et al., 2017; Ravishankar et al., 2015). 
Transposon insertion or deletion mutants of the E. coli topA gene (encoding topoisomerase 
I) were successfully isolated. However, attempts to isolate insertion or deletion mutants of 
the topA gene in M. tuberculosis or Helicobacter pylori were unsuccessful (Sassetti et al., 
2003; Suerbaum et al., 1998). Recent reports have confirmed that the silencing of the topA 
gene significantly affected the survival of M. tuberculosis (Ravishankar et al., 2015, 
Ahmed et al., 2014).  
E. coli topoisomerase I (EcTopoI) is involved in the removal of transcription-
driven negative supercoiling behind the RNA polymerase complex (Liu et al., 1987; Masse 
et al., 1999a). A loss of topoisomerase I function can possibly lead to the accumulation of 
R-loops (RNA-DNA hybrids) along with an increased torsional stress. A simultaneous 
depletion of the RNAse HI (an R-loop hydrolyzing enzyme) and topoisomerase I can have 
a severe effect on the viability due to interference in the transcription and replication 
processes by R-loop accumulation (Stockum et al., 2012). Although the active site is 
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located on the N-terminal domains D1-D4 of EcTopoI, the N-terminal fragment of D1-D4 
cannot catalyze the removal of the negative supercoiling by itself. The enzyme requires the 
C-terminal domains, along with the N-terminal domains D1-D4 for its activity (Terekhova 
et al., 2013). The C-terminal region has three zinc ribbon domains D5-D7 that can hold 
three zinc(II) ions and two zinc ribbon like domains D8-D9 (Tse-Dinh et al., 1988, Tan et 
al., 2015). Mutating the cysteine residues on the zinc ribbon motifs, or removal of the 
Zinc(II) rendered the enzyme inactive (Tse-Dinh, 1991; Zhu et al., 1995). 
 
  
 
 
  
 
 
 
 
Figure I.16.  Crystal structures of bacterial topoisomerase I; (A) Domain arrangement 
of M. tuberculosis topoisomerase I (MtbTopoI) (B) Crystal structure of MtbTopoI-704t 
(D1-D5) (Tan et al., 2016) (C) Domain arrangement of E. coli topoisomerase I (EcTopoI) 
(D) Crystal structure of full-length EcTopoI in complex with single stranded DNA (Tan et 
al., 2015). 
 
The most recent crystal structure of the full-length enzyme in coordination with a single 
stranded DNA has provided evidence for the role of the C-terminal domains D5-D9 in 
recognition and interaction with the hyper-negatively supercoiled DNA (Figure I.16 (D)) 
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(Tan et al., 2015). The enzyme utilizes both the N-terminal and C-terminal domains for the 
interactions with the hyper-negatively supercoiled DNA in relieving the supercoiling 
stress. Briefly, the N-terminal domains recognize and cleave a strand of DNA (Gate-strand) 
via its active site, whereas the zinc ribbon domains D5-D7 in the C-terminal region can 
bind the transfer-strand of the under-wound substrate, allowing the passage of the transfer 
strand through the gate (Figure I.15). The role of the C-terminal is not just limited to the 
binding under wound DNA, as literature has suggested its role in the protein-protein 
interactions. A direct interaction of the C-terminal region of EcTopoI with the RNA 
polymerase b’ subunit can ensure a smooth transcription elongation (Cheng et al., 2003). 
The topoisomerase I of M. tuberculosis (MtbTopoI) has been investigated for its 
potential as a novel drug target in the treatment of drug resistant tuberculosis. Unlike in E. 
coli, the pathogen M. tuberculosis has only one representative of type I (MtbTopoI), and 
type II topoisomerase (gyrase). The MtbTopoI relaxes the topological strain on the DNA 
by cutting and religating a single-strand of DNA, much like E. coli topoisomerase I. 
Genetic studies have provided an evidence for the indispensability of the only type I 
topoisomerase (MtbTopoI) in M. tuberculosis (Ahmed et al., 2014). M. smegmatis, a non-
pathogenic mycobacterium, also has only one type IA topoisomerase (MsmTopoI). Genetic 
studies on the topoisomerase I-depleted strain has provided evidence for the essentiality of 
MsmTopoI in the growth and nucleoid architecture (Ahmed et al., 2015). Mycobacterial 
topoisomerase I is devoid of the Zinc-binding tetra-cysteine motifs, unlike the E. coli 
topoisomerase I. The N-terminal domains of topoisomerase I are highly conserved among 
different bacteria, whereas the C-terminal domains are highly variable.  A crystal structure 
of the MtbTopoI-704t (N-terminal domains: D1-D4, and C-terminal domain: D5) was 
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recently published (Figure I.16 (B)) (Tan et al., 2016). The MtbTopoI-704t was sufficient 
for the DNA cleavage-religation activity, and single stranded DNA catenation but not for 
relaxation of negatively supercoiled DNA (Tan et al., 2016). The C-terminal region of 
mycobacteria and other actinobacteria are divergent from the other bacterial species, and 
contains three basic stretches that are required for binding with the non-scissile strand of 
DNA, allowing the strand passage through the cleaved strand (Ahmed et al., 2013). Recent, 
X-ray crystallography structural studies showed that the Mycobacterium tuberculosis 
topoisomerase I C-terminal domains (CTD) are formed by repeats of a novel protein fold 
of a four-stranded antiparallel β-sheet stabilized by a crossing-over α-helix (Tan et al., 
2016).   
 
OVERVIEW 
 
The topological state of DNA is managed by a group of enzymes called topoisomerases. 
Essential cellular processes like transcription, replication, recombination and DNA repair 
create topological problems for DNA. There is a consensus in the scientific community 
about the role of topoisomerases in addressing the topological problems of DNA generated 
during the above-mentioned processes. The indispensability of these enzymes for the 
viability of a cell have made them the potential targets of antibiotic and anticancer drugs. 
However, the potential for success depends on how well we understand the in vivo behavior 
of topoisomerases. The goal of my research is to understand the functional association 
network of bacterial topoisomerase I by studying its protein-protein interactions. In chapter 
1, the molecular mechanism of interaction between E. coli RNA polymerase and 
topoisomerase I was elucidated. The protein interaction between RNA polymerase beta’ 
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subunit and topoisomerase I of E. coli was previously reported, and the association is 
believed to resolve the transcription driven hyper-negative supercoiling. The key amino 
acid residues of topoisomerase I and RNA polymerase favoring the interaction are 
predicted by molecular docking, and molecular dynamic simulations. The effect of 
mutating some of the key topoisomerase I residues on the interaction between RNA 
polymerase and topoisomerase I was also reported. In chapter 2, the protein-protein 
interactions of M. smegmatis topoisomerase I were analyzed by pull-down and co-
immunoprecipitation assays (Co-IP) coupled to mass spectrometry. The interaction of 
RNA polymerase with topoisomerase I in M. smegmatis was established by both pull-
down, and Co-IP. In chapter 3, the mechanism of interaction and the physiological 
relevance of the RNAP-topoisomerase I interaction in M. smegmatis was explored. A novel 
mechanism of interaction through the C-terminal tail of topoisomerase I was reported. In 
chapter 4, the molecular basis for stimulation of E. coli topoisomerase I catalytic activity 
by RecA was investigated. To study physical interactions as the basis of stimulation of 
topoisomerase I activity by RecA, the physical interactions were examined by molecular 
docking, pull-down assays, and surface plasmon resonance. The experimental evidence 
supported a direct physical interaction of E. coli RecA with the N-terminal domains of 
topoisomerase I. 
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CHAPTER 1 
MOLECULAR MECHANISMS OF INTERACTION BETWEEN E. COLI RNA 
POLYMERASE AND TOPOISOMERASE I 
 
ABSTRACT 
 Escherichia coli topoisomerase I (EcTopoI), a type IA DNA topoisomerase, 
physically and functionally interacts with RNA polymerase (RNAP) during the 
transcription process. EcTopoI, an enzyme responsible for relieving the negative 
supercoiling, is recruited by RNAP beta’ subunit for resolving the transcription associated 
hyper-negative supercoiling. Structural information of the RNAP-EcTopoI complex is 
required for understanding the basis of protein-protein interaction. The potential structure 
of the complex was predicted by molecular docking, and molecular dynamic simulations. 
Surface plasmon resonance (SPR) provided a quantitative measure of the interaction 
(KD=~93 nM). The docking studies predicted salt bridging and hydrogen bonding as the 
driving force for interaction of the RNA Polymerase beta’ subunit with the C-terminal 
domain of topoisomerase I in E. coli. Residues 609 (Arginine), 627 (Lysine), and 664 
(Lysine) of EcTopoI were predicted, by docking, to be involved in the salt bridge and 
hydrogen bond formation with RNAP beta’ subunit. Supporting the docking prediction, 
pull-down assays with a double mutant EcTopoI (K627,664A) created in this study via 
site-directed mutagenesis confirmed a significant reduction in the interaction with RNA 
polymerase.  
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INTRODUCTION 
 Transcription initiation, elongation, and termination is driven by DNA-dependent 
RNA polymerase (RNAP) across domains of life (Ray-Soni et al., 2016; Vassylyev et al, 
2007; Feklistov, 2013; Vassylyev, 2009). The core subunits of RNAP share a high degree 
of homology in prokaryotes and eukaryotes (Sweetser et al., 1987; Cramer, 2002, Ebright, 
2000). The progression of the RNAP complex along the DNA template during transcription 
elongation can create hyper-negative supercoiling behind the complex, and Positive 
supercoils ahead of it (Liu et al.,1987; Vos et al., 2011; Ma et al., 2013). The supercoiling 
problem needs to be addressed for an unhindered transcription process, and topoisomerases 
are involved in relieving such tension on the DNA (Wu et al., 1995).  
Other essential cellular processes including replication, repair, and recombination 
also require the activities of topoisomerases for genomic stability. Bacterial topoisomerase 
I, a type IA DNA topoisomerase, relaxes negative supercoils in DNA (Champoux, 2002a). 
Escherichia coli topoisomerase I (EcTopoI), the most widely studied bacterial type IA 
topoisomerase, consists of 865 amino acid residues organized into N-terminal domains D1-
D4 and C-terminal domains D5-D9 (Figure I.16, C). EcTopoI can bring about the 
relaxation of negatively supercoiled DNA by forming a transient 5’ phosphotyrosine 
linkage with a single strand of DNA through its active site residue-Y319 (Lynn & Wang, 
1989). R-loop formation and a friction in the transcription elongation process can occur in 
the absence of EcTopoI activity (Drolet et al., 1995; Masse et al., 1999b). The functional 
association of RNAP-EcTopoI may require a physical association of these proteins. 
Previous reports have verified a direct physical interaction of the C-terminal domain of 
topoisomerase I (EcTopoI-CTD) with the RNAP beta’ subunit (Cheng et al., 2003). 
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However, information regarding the structure of the protein-protein interaction complex 
and molecular mechanism of the interaction remained to be elucidated. In silico molecular 
docking, and molecular dynamic simulations were performed for predicting the binding 
modes, and identification of the amino acid residues involved in the complex formation. 
Prediction of the structure of a protein-protein complex (Smith et al., 2002; Gray et al., 
2003) and binding interface (Xue et al., 2015) has been made possible by molecular 
docking.  The affinity and strength of a biomolecular interaction can be studied by a widely-
used label free technique, surface plasmon resonance (SPR) (Tiwari et al., 2014; Elass et 
al., 2007; Tiwari et al., 2015). Equilibrium dissociation constant (KD), a parameter for 
measuring the binding affinity, can be determined by SPR (Kastritis et al., 2013). SPR was 
used for the quantitative characterization of the interaction between RNAP and EcTopoI.  
The conformational dynamics of proteins as flexible macromolecules can be related 
to its function (Karplus et al., 2002). In silico studies can provide insights into the influence 
of a protein conformation on its binding partner and the strength of binding (Singh et al., 
2016). The structural features of RNAP-EcTopoI complex were modelled by all-atom 
molecular dynamic simulations of the complex predicted by molecular docking. The 
docking studies, and all-atom molecular dynamic simulations complemented the 
experimental evidence for interaction between RNAP beta’ subunit and the C-terminal 
domain of EcTopoI (Cheng et al., 2003). The RNAP-EcTopoI complex was stable for 
entirety, 150 nanoseconds, of simulation. Stable hydrogen bonds are established between 
S1117 (RNAP) and K664 (EcTopoI), V697 (RNAP) and K664 (EcTopoI). As the complex 
establishes further inter-protein interactions, the RNAP β' subunit undergoes a significant 
structural rearrangement favoring the salt bridge formation between E874 (RNAP) and 
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K627 (EcTopoI), E1009 (RNAP) and R609 (EcTopoI). It is possible that the hydrogen 
bonding initiates the EcTopoI-RNAP complex formation, and supports the structural 
flexibility of the RNAP β' subunit without breaking the complex.   In this study, the lysine 
residues predicted to be essential for hydrogen bonding and salt bridge formation were 
mutated to alanine. The mutant recombinant EcTopoI proteins were expressed and purified. 
The effect of these site-directed mutations on the complex formation with RNAP was 
verified by pull-down assays. 
 
MATERIALS AND METHODS 
Bacterial strains and plasmids 
E. coli strain BW25113 (Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-
1, Δ(rhaD-rhaB)568, hsdR514), obtained from Yale CGSC (Datsenko and Wanner, 2000), 
was used for preparing the cell lysate used in the pull-down of RNAP from total soluble 
cellular proteins.  Plasmid, pLIC-ETOP transformed into E. coli BL21-AI was used for the 
expression and purification of recombinant E. coli topoisomerase I with 6x-His tag 
(Sorokin et al., 2008).  The mutant plasmids (pLIC-ETOP(K627A), pLIC-ETOP(K664A), 
pLIC-ETOP (K627,664A)) were constructed by site directed mutagenesis of pLIC-ETOP. 
The plasmids were transformed separately into E. coli BL21 STAR DE3 (Invitrogen) for 
overexpression, and purification of the mutant EcTopoI.  A pET His6-Mocr TEV cloning 
vector (2O-T) (gift of Scott Gradia, Addgene #29710) was used for expression and 
purification of a recombinant viral protein, His-Mocr (DelProposto et al., 2009) that was 
used as negative control in the pull-down assays.  
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 Table 1. T1. Primers used in Site-Directed Mutagenesis  
 
 
Primer Sequence (5’-3’) Description 
pLIC-ETOP_K627A_FP GCTGCCGCCGGCAGAGCGTTGCA  Lysine 627 of EcTopoI is mutated 
to Alanine 
 
pLIC-ETOP_K627A_RP GCATAGCCAGAACAGCCAAGG  
pLIC-ETOP_K664A_FP TCGTTGCCCGGCATGCGGCACGG  Lysine 664 of EcTopoI is mutated 
to Alanine 
 
 
pLIC-ETOP_K664A_RP CGTTTTGCGCGCAGCGCG  
pLIC-ETOP_K627,664A_FP	
GCTGCCGCCGGCAGAGCGTTGCA, 
TCGTTGCCCGGCATGCGGCACGG 
	 Lysine 627 and 664 of EcTopoI is 
mutated to Alanine (Double 
mutant) 
	pLIC-ETOP_K627,664A_RP	 GCATAGCCAGAACAGCCAAGG, CGTTTTGCGCGCAGCGCG	
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Protein purification 
E. coli topoisomerase I with a N-terminus 6x-Histidine tag (His-EcTopoI) was 
expressed from pLIC-ETOP in E. coli BL21-AI by induction with 1 mM IPTG, 0.02% L-
Arabinose as described previously (Sorokin et al., 2008). Mutant E. coli topoisomerase I 
with a N-terminus 6x-Histidine tag was expressed from a mutant pLIC-ETOP plasmid in 
BL21 Star (DE3) by induction with 1 mM IPTG.  Expression of recombinant His-tagged 
Mocr was induced in BL21 star (DE3) with 1 mM IPTG. Protein purification was carried 
out with a PrepEase Histidine-tagged protein purification maxi kit (Affymetrix; 78805), 
according to the recommended manufacturer’s protocol. 
 
Relaxation assay 
The in vitro relaxation activity of the purified mutant EcTopoI enzyme was 
compared with the wild-type enzyme. A supercoiled pBAD/Thio plasmid DNA substrate 
(160 ng), purified by Cesium Chloride gradient method, was incubated with different 
amounts of the enzyme in the presence of 5 mM MgCl2 (Sandhaus et al., 2016). The 
reaction mixture was setup at 37°C for 30 minutes. The reaction was terminated by the 
addition of stop buffer (50 mM EDTA, 50% glycerol, 0.5% v/v bromophenol blue), and 
the reaction products were electrophoresed on a 1% agarose gel and then stained with 
ethidium bromide for visualization of the DNA.  
 
 
Molecular docking 
 
  The structure of the E. coli RNAP core enzyme was taken from protein data bank 
(PDB) [PDB entry 3LU0 (Opalka et al., 2010)]. Protein coordinates in the PDB entry 4RUL 
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(Tan et al., 2015) was taken as the full-length structure of EcTopoI. Molecular docking 
between these two proteins was performed by Dr. Tiwari using the PatchDock web server 
(Duhovny et al., 2002 & 2005). The top 100 predictions from the PatchDock docked 
complexes were refined using FireDock web server (Mashiach et al., 2008; Andrusier et 
al., 2007). The best-ranked complex with the lowest energy (highest affinity) from the 
FireDock output was considered as the RNAP-EcTopoI complex for further analysis. 
 
Surface plasmon resonance (SPR) 
 Biacore T200 SPR instrument was used to determine the KD value for RNAP-
EcTopoI complex formation. Recombinant EcTopoI (ligand) expressed and purified, as 
described previously (Sorokin et al., 2008), was immobilized onto series S CM5 sensor 
chip (GE Healthcare) via standard amine coupling chemistry. Various concentrations of 
RNAP core enzyme (New England BioLabs) were used as analyte to flow (in duplicates or 
triplicates) over the ligand-immobilized surface at a flow rate of 50 µL/min. 20 mM Tris-
HCl (pH7.5) supplemented with 100 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 10 mM 
MgCl2, 0.005% Tween-20 and 5% glycerol was used in the RNAP-EcTopoI SPR binding 
experiments. 1M NaCl was used to regenerate the sensor surface. SPR experiments were 
carried out at 25oC.  
 
Molecular dynamics (MD) Simulations 
 All-atom MD simulations were carried out with the NAMD simulation package 
(Phillips et al., 2005). The interacting domains of RNAP-EcTopoI complex were 
considered for the simulation studies. These domains consisted of residues 788-1317 from 
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the RNAP β' subunit and residues 594-705 from EcTopoI. Two Zn2+ ions bound to the 
tetracysteine motifs are within this selected EcTopoI region (594 to 705). The input 
files/parameters for MD simulations were generated by CHARMM-GUI (Lee et al., 2016) 
using CHARMM36 force field. The complex was solvated in a cubic box with TIP3 water 
and the system was electrically neutralized by adding ten Mg2+ and four Cl- ions. The 
resulting dimension of the solvation box was 120 x 120 x 120 Å3, containing 164,880 
atoms. The MD simulations of the complex started with 10,000 steps of energy 
minimization with the conjugate gradient and line search algorithm. The Particle Mesh 
Ewald (PME) (Darden et al., 1993) method was used for the long-range interactions with 
12Å non-bonded cut-off. The system was equilibrated at 300 K (27oC) for 100 ps with 
protein heavy atoms harmonically restrained at a 1 fs integration time step, followed by a 
4-ns NPT run with fully unrestrained protein using a 2 fs time step. The simulation was 
then propagated with Langevin dynamics with a damping constant of 1 ps−1. The complex 
was then simulated for 150 ns under NVT condition with a time step of 2 fs.  
 
Data analysis 
Biaevaluation software version 2.0 was used to evaluate the SPR sensorgrams and 
determine the KD value via steady state affinity analysis. Each frame in the simulation 
trajectory file was saved at every 20 ps. VMD (Humphrey et al., 1996) was used to 
visualize the structure and analyze the simulation trajectories.  
 
 
 
 40 
Pull-down assays on E. coli soluble cell lysate  
In this assay, E. coli strain (BW25113) cultured in LB medium for 16 hours to 
stationary phase (OD600=2.5), and the culture was pelleted. The cell pellet was suspended 
in the pull-down buffer containing 1mg/ml lysozyme. The suspended cells were subjected 
to lysis by four freeze-thaw cycles. The lysate was centrifuged at 13000xg for 2 hours at 
4°C. The soluble protein fraction was incubated (precleared) with HisPur Cobalt Agarose 
resin before its use in the pull-down reaction. The preclearing minimizes non-specific 
binding of proteins to the beads. Either purified wild type EcTopoI or mutant EcTopoI was 
used as bait. A Bacteriophage T7 protein, Mocr, with a N-terminus 6x-His tag was used as 
bait in the negative control for the pull-down assay (DelProposto et al., 2009). Bait (40 
nM), and precleared soluble protein fraction (200 µg) were incubated at 4°C for 2 hours. 
HisPur Cobalt agarose resin (Thermofisher) was added to the reaction, and incubated 
overnight at 4°C. On the following day, the resin-reaction mixture was spun, and the 
supernatant was discarded. The bead pellet was washed three times in pull-down buffer 
with 10 mM imidazole to minimize non-specific binding of histidine rich proteins to the 
resin. The proteins bound to the resin were finally eluted in 400 mM imidazole, and the 
eluates were subjected to SDS-PAGE analysis. A western blot was performed to probe for 
RNA polymerase using a monoclonal antibody against RNA polymerase beta 
(BioLegend). 
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RESULTS AND DISCUSSION 
Salt bridges and hydrogen bonds drive the complex formation 
The molecular docking and molecular dynamic simulations have provided the 
structural information of the RNAP-EcTopoI complex. The computational models agree 
with the experimental evidence, as the binding interface predicted by the modeling also 
involves the RNAP β' subunit and the C-terminal of EcTopoI (Cheng et al., 2003). The 
structure of the most favorable RNAP-EcTopoI complex, predicted by PatchDock and 
refined by FireDock is shown in Figure 1.2, A.  
Analysis of the RNAP-EcTopoI complex interface (Fig. 1.2, E) after the energy 
minimization shows that several hydrogen bonds, ionic, and van der Waals interactions are 
involved in forming and stabilizing the RNAP-EcTopoI complex. The interfacial contacts 
involve mainly the residues in the EcTopoI loop segments that are stabilized by Zn2+ co-
ordinations at the two ends. Specifically, inter-protein salt-bridge interactions between 
E873 (RNAP) and K627 (EcTopoI), and between K959 (RNAP) and E628 (EcTopoI) 
occur at the interface involving one of the Zn2+ bound loop of the EcTopoI-CTD. Other 
specific interactions include hydrogen bond between S876 (RNAP) and E628 (EcTopoI), 
and between V967 (RNAP, backbone) and K664 (EcTopoI, side chain). Although these 
salt-bridge and hydrogen bond interaction pairs change over the course of MD simulation, 
the residues involved in such interactions represent the recognition sites for EcTopoI-CTD 
binding to RNAP. Remarkably, the EcTopoI region that binds to RNAP is very close to 
the location where it binds the single stranded DNA in the crystal structure of the EcTopoI-
DNA complex (Figure 1.2, F), making the inter-protein interactions in this region 
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functionally relevant, as the DNA may be an extension of the RNAP transcription 
elongation complex.  
The stability of the complex was assessed by all-atom MD simulations in an explicit 
solvent. A significant rearrangement of the interfacial contacts was observed. The final 
structure the complex at the end of the 150 ns NVT simulation is shown in Figure 1.3, A. 
The contacts are observed in three different sites, two of which involves residues in the 
loop segments that are stabilized by the Zn2+ co-ordinations at the two ends of EcTopoI. 
Relatively more stable interfacial contacts are made in the Zn2+ coordinated loop involving 
K664. Specifically, the positively charged K664 (EcTopoI) side chain forms two hydrogen 
bonds: with the S1117 side chain and the V967 backbone (RNAP β' subunit). Slight 
structural rearrangements yield two new salt-bridges K627 (EcTopoI)-E874 (RNAP) and 
R609 (EcTopoI)-E1009 (RNAP) to replace the two originally observed ionic interactions 
K627 (EcTopoI)-E873 (RNAP) and E628 (EcTopoI)-K959 (RNAP). The salt-bridge 
interaction between R609 (EcTopoI) and E1009 (RNAP) occurs about midway between 
the Zn2+ coordinated sites. The amino acid residues in EcTopoI that establish salt-bridges 
with RNAP are generally conserved among various bacterial species (Fig. 1.3, C). 
Interestingly, when lysine in position 664 is replaced by isoleucine, its binding counterpart 
serine in position 1117 is also replaced by isoleucine or valine. This makes it possible for 
these residues to potentially interact via hydrophobic interactions. The K664 of EcTopoI, 
responsible for a stable hydrogen bonding with RNAP, helps in latching on to RNAP β' 
subunit and stabilizing the complex.  
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EcTopoI-RNAP have high binding affinity 
 SPR analysis was carried out for determining the equilibrium dissociation constant 
(KD) of the complex. The steady state response values (shaded grey area in Fig. 1.2, C) 
were plotted against the RNAP concentration (Fig. 1.2, D) and were evaluated using 
Biaevaluation software version 2.0 via steady state affinity model fitting. The calculated 
KD value for RNAP-EcTopoI complex was ~93 nM, indicating a strong affinity between 
these proteins.  
Figure 1.1. MD simulation of mutant EcTopoI (K664A) in complex with RNAP at 
different times of the simulation trajectory. (A) Structure of the complex at 0 ns (B) 
Dissociation of the complex at 45 ns. 
 
Salt bridging and hydrogen bonding are essential for the complex formation 
Molecular docking and MD simulations have predicted the RNAP-EcTopoI 
complex formation through salt-bridging, and hydrogen bonding. According to these 
studies, the K664 plays a significant role in the complex formation and stabilization. The 
MD simulation studies on the RNAP-EcTopoI complex formation by mutating the K664 
of EcTopoI to alanine resulted in the dissociation of the complex in 45 ns (Figure 1.1, B). 
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The experimental evidence for the significance of lysine residues (K627, K664 of EcTopoI) 
in RNAP-EcTopoI interactions was verified by Pull-down assays.  
The wild type, and mutant EcTopoI (K627A, K664A & K627,664A) with a 6xHis 
tag on the N-terminus was purified, and used as a bait in the pull-down assays. The 
relaxation activity of the purified mutant enzymes was no different from the wild type 
EcTopoI (Figure 1.4, A). Mutating the lysine 627 or 664 of EcTopoI to alanine has caused 
a reduction in binding with RNAP (Lane 4, 5 of Figure 1.4, B). When both the lysine were 
mutated to alanine, there was significant reduction in binding with RNAP (Lane 6 of Figure 
1.4, B). The diminished binding can be attributed to the inability of the mutated EcTopoI 
to form salt bridges and hydrogen bonds with RNAP beta’ subunit.  
 
CONCLUSIONS 
The formation and stabilization of the RNAP-EcTopoI complex using MD 
simulations was investigated. The SPR measurements suggest a strong binding affinity 
between RNAP and EcTopoI (KD= ~93 nM). The RNAP-EcTopoI complex structure was 
generated by molecular docking, optimized and analyzed with all-atom MD simulations. 
Consistent with the previous experimental result, the predicted binding interface involves 
the RNAP β' subunit and EcTopoI-CTD. The complex was stable throughout the 150 ns of 
MD simulation. The amino acid residues involved in the formation and stabilization of the 
protein complex were identified. Two salt-bridges between E874 (RNAP) - K627 
(EcTopoI), and E1009 (RNAP) - R609 (EcTopoI) as well as two hydrogen bonds between 
S1117 (RNAP) - K664 (EcTopoI), and V967 (RNAP) - K664 (EcTopoI) comprise the 
major interfacial interactions in the RNAP-EcTopoI complex. Upon EcTopoI binding, 
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RNAP was found to undergo conformational rearrangements, facilitating the inter-protein 
interactions. The mutant complex with the K664A substitution is found to be unstable, 
according to the simulation studies. The removal of the specific interactions involving 
K664 and S1117 allows the complex to dissociate, with no inter-protein contacts left after 
40 ns of simulation. However, according to the pull-down experiments, mutating the 
EcTopoI K664 alone did not hinder the association with RNAP, although a reduction in 
the binding was noticed. There was a significant effect on the complex formation, when 
both the lysine (627, and 664) were mutated to alanine. Based on these observations, it can 
be speculated that the EcTopoI loop, containing K627 and K664, is responsible for the 
initiation of the complex formation. Since this loop is stabilized by Zn2+ coordination, it is 
possible that the Zn2+ coordination might also be important for the complex formation. It 
will be interesting to study the in vivo response of bacteria, when the amino acids residues 
critical for RNAP-EcTopoI complex formation are mutated. The RNAP-topoisomerase I 
interactions are essential for relieving the transcription driven hyper-negative supercoiling, 
and it is possible that this association is conserved across different life forms. In chapter 3, 
a novel mechanism of RNAP-Topoisomerase I interaction in mycobacteria is discussed.  
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Figure 1.2. Association of RNAP-EcTopoI (Tiwari et al., 2016). (A) The complex, RNAP-EcTopoI, as predicted by docking. 
[RNAP: Orange (RNAP β' subunit) and gold-colored structure; EcTopoI-CTD: Dark green; EcTopoI-NTD: Light green]. The red 
dotted circles highlight the regions of RNAP β' subunit and EcTopoI-CTD selected for simulation studies. (B) Cartoon representation 
of the complex (C) SPR sensogram of analyte (RNAP) binding to immobilized ligand (EcTopoI) on a CM5 sensor chip (D) Steady 
state response values (Req, grey shaded area in C) plotted as a function of RNAP concentration. (E) Cartoon structure of the complex, 
showing interfacial residues in contact after energy minimization. (F) EcTopoI-ssDNA bound structure (PDB ID: 4RUL) [Magenta: 
ssDNA] 
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Figure 1.3. Residues involved in the EcTopoI-RNAP complex formation (Tiwari et al., 2016). (A) RNAP-EcTopoI complex 
after 150 ns of NVT simulations. (B) Distance between the predicted amino acid residues involved in the complex formation, over 
a 150 ns trajectory. (C) Sequence alignment of Topoisomerase I and RNAP β' subunit across bacteria. The residues having a potential 
for salt bridge and hydrogen bond formation are highlighted in blue transparent boxes. 
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Figure 1.4. Lysine 627, 664 are essential for complex formation with RNAP. (A) Relaxation assays were carried out with Wild 
type, and Mutant enzymes. The reactions were set up at 37°C for 20 minutes in the presence of 5 mM MgCl2 (B) Pull-down of RNAP 
from E. coli soluble lysate by recombinant wild type EcTopoI (Lane 3) or mutant EcTopoI (Lane 4, 5, 6). Negative control: Pull-
down with recombinant Mocr (Lane 2). RNAP in the lysate did not by itself bind to the beads (Lane 1). (C) Graph representing 
average values of RNAP beta band intensities, from three independent pull-down experiments, relative to the RNAP beta band 
intensity in the negative control. The error bars represent standard deviations of three measurements. 
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CHAPTER 2 
IDENTIFICATION OF PROTEIN PARTNERS OF MYCOBACTERIAL 
TOPOISOMERASE I 
 
ABSTRACT 
Protein-protein interactions (PPIs) drive essential cellular processes including DNA 
replication, transcription, translation, recombination, and repair. The activities of DNA 
topoisomerases are required for a normal relay of these processes. The functional 
association of topoisomerases with proteins involved in these processes is anticipated for 
maintaining the genomic stability. The physiological pathways in which topoisomerases 
are involved can be envisaged by identifying their protein partners. In this chapter, the 
protein-protein interactions of M. smegmatis DNA topoisomerase I, an enzyme that can 
relax excessive negative supercoiling, were investigated. Co-immunoprecipitation studies 
using antibodies against mycobacterial topoisomerase I, and pull down assays using 
recombinant M. smegmatis topoisomerase I were implemented, and the protein partners 
were identified by mass spectrometry. RNA polymerase was identified as a potential 
partner of topoisomerase I by these approaches. Putative DEAD/DEAH Box helicase 
(MSMEG_1930) was identified as a physical partner through Pull-down assays. 
Knowledge gained from this study can provide valuable insights into the physiological 
functions of a potential drug target, DNA topoisomerase I, in pathogenic mycobacteria. 
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INTRODUCTION 
World health organization’s global health report (2016) has declared 
Tuberculosis(TB) to be one of the world’s deadliest communicable diseases. 
Mycobacterium tuberculosis, an aerobic rod shaped bacteria, is the causative agent of 
tuberculosis, although, other species of Mycobacterium (M. bovis, M. africanum, M. 
canetti etc.) can cause the disease in immune-compromised patients (Addo et al., 2007). A 
major roadblock, in the treatment of TB, is the development of multidrug resistant (MDR) 
and totally drug resistant (TDR) TB strains (Plocinski et al., 2014). Identification, and 
targeting of novel drug targets in the pathogenic mycobacteria could serve as a promising 
approach in the treatment of refractory tuberculosis.  
DNA topoisomerases, topoisomerase I and gyrase, are validated drug targets in M. 
tuberculosis (Nagaraja et al., 2017). The genome-wide distribution profile of DNA 
topoisomerases, topoisomerase I and gyrase, relative to RNA polymerase in M. 
tuberculosis by Chromatin immunoprecipitation sequencing (ChIP-seq) revealed their 
localization on the active transcriptional units. The topoisomerase I and gyrase were 
localized behind and ahead of the RNA polymerase respectively, suggesting their role in 
resolving the transcription driven supercoiling (Ahmed et al., 2017). The activities of these 
enzymes are not just limited to the transcription process, they are believed to maintain the 
topology of DNA during other essential processes involving DNA transactions (Nagaraja 
et al., 2017; Wang, 2002). Although gyrase has been extensively targeted by clinically 
successful fluoroquinolones, the bacterial topoisomerase I is not yet exploited as a target 
for clinical antibiotics (Nagaraja et al., 2017). The development of quinolone resistance 
has posed a threat for the treatment of TB and other bacterial infectious diseases (Andrea 
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et al., 2009). Hence, topoisomerase I – the only type IA topoisomerase in mycobacteria can 
serve as an alternative drug target (Tse-Dinh, 2007). The presence of only one type IA 
topoisomerase in mycobacteria, and its essentiality for the growth and survival of the 
pathogen (Ahmed et al., 2014), has made this enzyme a validated TB drug target (Nagaraja 
et al., 2017; Ravishankar et al., 2015; Tse-Dinh, 2015). In vitro and in vivo loss in viability 
of M. tuberculosis H37Rv was reported when the intracellular topoisomerase I levels were 
depleted, demonstrating the essentiality of this enzyme (Ravishankar et al., 2015).  
In order to fully understand the physiological function of mycobacterial 
topoisomerase I, elucidating the protein-protein interactions involved with this essential 
enzyme is critical.  It would be ideal to perform studies on M.  tuberculosis, a biosafety 
level-3 pathogen. Since, the department of environmental health and safety at FIU strictly 
prohibits working with Biosafety level 3 and 4 pathogens, a non-pathogenic and 
evolutionarily closely related model organism, M. smegmatis, was utilized for my studies. 
It should be noted that studies carried out on M. tuberculosis in chapter 3, were carried out 
with the whole cell lysates purchased from ATCC (NR-14822).  
The topology of DNA is maintained by an important group of evolutionarily 
conserved enzymes called topoisomerases (Wang, 2002). The essential cellular processes 
including replication, transcription, recombination, and repair create topological strain on 
the double helix of DNA (Champoux, 2002a). Topoisomerases, acting in concert, 
transiently cleave and rejoin DNA to resolve the strain, and maintain the genomic stability. 
Topoisomerases are placed in two families, type I and type II, depending on the number of 
strands cleaved during each catalytic cycle.  Further, in view of their structural and 
mechanistic differences, topoisomerases are divided in to subfamilies of IA, IB, IIA, and 
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IIB. In this chapter, the focus will be channeled at studying mycobacterial type IA 
topoisomerase. The type IA topoisomerases (excluding reverse gyrase) recognize, nick a 
single strand of DNA by forming a transient 5’-phospotyrosine covalent linkage, and relax 
the negatively supercoiled DNA via “enzyme-bridged strand passage mechanism” (Wang, 
1971; Viard et al., 2007). A notable feature of M. tuberculosis is the presence of a single, 
indispensable, type IA topoisomerase.  Mycobacterial topoisomerase I, thus, can serve as 
a potential drug target in the TB therapy. All the currently available topoisomerase 
targeting antibacterial drugs are inhibitors of topoisomerase II, and so far, potent and 
specific inhibitors against bacterial topoisomerase I remained to be discovered (Nagaraja 
et al., 2002). Investigating the protein partners of mycobacterial topoisomerase I, and 
deciphering the necessity of the interaction in the viability will open up new avenues in the 
treatment strategies. Targeting the interface of an essential protein-protein interaction by a 
novel fragment based drug discovery approach has shown promise (Scott et al., 2012, Scott 
et al., 2013). For instance, the interface of protein-protein interactions between a tumor 
suppressor BRCA2 and a recombinant enzyme RAD51 was targeted by the fragment-based 
approach. The disruption of BRCA2-RAD51 interaction can possibly lead to a cellular 
hypersensitivity to radiation and genotoxic drugs (Scott et al., 2013). 
The protein partners of type IA topoisomerase may define the physiological roles 
of the enzyme (Viard et al., 2007). The type IA topoisomerases contain evolutionarily 
conserved core N-terminal domains (NTD) enclosing the active site (Wang, 1996; Berger, 
1998; Champoux, 2001), and C-terminal domains (CTD) highly variable in size and 
sequence. The mycobacterial topoisomerase I lacks the tetracysteine zinc ribbon motifs in 
its CTD, unlike E. coli topoisomerase I. Recently, it was reported that a nucleoid associated 
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protein of M. tuberculosis, MtHU, physically and functionally interacts with the CTD of 
topoisomerase I. The nucleoid associated protein, HU, can stimulate the DNA relaxation 
ability of topoisomerase I by a direct physical interaction (Ghosh et al., 2014). According 
to this report, the protein-protein interaction regulates the topoisomerase I activity by 
enhancing the strand passage activity of topoisomerase I. The CTD of topoisomerase I was 
also reported to physically and functionally interact with MazF protein Rv1495. According 
to this report, the protein-protein interactions have a negative effect on the activities of 
topoisomerase I and Rv1495. The physical interaction inhibited the relaxation activity of 
topoisomerase I, and the mRNA cleavage activity of Rv1495 (Huang et al.,2010). Both the 
reports suggested a regulation of topoisomerase I activity by protein-protein interactions.  
 
 
 
 
 
Figure 2.1. A comparison of type IA topoisomerases showing highly-conserved N-
terminal domains (NTD), and variable C-terminal domains (CTD). htop3a: Human 
topoisomerase III alpha, htop3b: Human topoisomerase III beta, Ec topA: E. coli 
topoisomerase I, Ec topB: E. coli topoisomerase III, My topA: Mycobacterial 
topoisomerase I. Tetracysteine Zinc ribbon motif. 
 
In the current study, novel protein partners of mycobacterial topoisomerase I were 
explored by a combination of pull-down and co-immunoprecipitation assays coupled to 
mass spectrometry. The study is based on the hypothesis that the CTD of mycobacterial 
topoisomerase I could be involved in protein interactions, among its other functions.  
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MATERIALS AND METHODS 
Bacterial strains, plasmids, and cloning 
M. smegmatis mc2 155 was obtained from ATCC and cultured in LB-Tween 80 
(0.1%). Overexpression of M. smegmatis topoisomerase I (MsmTopoI) in E. coli BL21 
STAR DE3 (Invitrogen) for protein purification was achieved from a vector, pET His6 
Mocr TEV LIC cloning vector (2O-T, Addgene Plasmid# 29710), Gibson cloned with 
MsmtopA gene. M. smegmatis RNAP beta (RpoB), RNAP beta’ (RpoC), Putative 
DEAD/DEAH Box helicase (MSMEG_1930), and M. tuberculosis H37Rv Putative ATP 
dependent RNA helicase (RhlE) genes were Gibson cloned separately into the SspI site of 
pLIC-HK, and transformed into E. coli SoluBL21 (Genlantis) cells for protein expression 
and purification. The PCR primers used in the cloning are listed in the Table 2. T1. 
 
Protein expression and purification 
The recombinant histidine tagged proteins – full length M. smegmatis DNA 
topoisomerase I (MsmTopoI) and fragment containing the C-terminal domains of 
Topoisomerase I (MsmTopoI-CTD) were purified initially for the pull-down assays with 
the M. smegmatis soluble lysate. Later, the potential partners of topoisomerase I, identified 
by coupling mass spectrometry to the pull-down assays, were purified for verifying a direct 
physical interaction. Basing on the mass spectrometry data, recombinant histidine tagged 
proteins of M. smegmatis RNAP beta subunit, RNAP beta’ subunit, Putative DEAD/DEAH 
Box helicase were purified for further studies.  A homologue of putative DEAD/DEAH 
Box helicase in M. tuberculosis H37Rv, ATP-dependent RNA helicase, was also expressed 
and purified with a recombinant Histidine tag for further studies. Overexpression of these 
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recombinant proteins in the E. coli hosts was induced with 1 mM IPTG. Following the 
overexpression and cell lysis, recombinant proteins were purified to near homogeneity by 
affinity chromatography using Ni-Sepharose 6 Fast flow beads (GE Healthcare Life 
Sciences) followed by size-exclusion chromatography.  The details of the purification are 
elaborated in chapter 3. 
 
Relaxation assay 
The in vitro relaxation activity of the purified topoisomerase I was tested. A 
supercoiled pBAD/Thio plasmid DNA substrate (160 ng), purified by cesium chloride 
gradient centrifugation method, was incubated with different amounts of the enzyme in the 
presence of 5mM MgCl2 (Sandhaus et al., 2016). The reaction mixture was setup at 37°C 
for 30 minutes. The reaction was terminated by the addition of stop buffer (50 mM EDTA, 
50% glycerol, 0.5% v/v bromophenol blue), and the reaction products were 
electrophoresed on a 1% Agarose gel and visualized over UV light following ethidium 
bromide staining. The effect of a putative helicase on the relaxation activity of M. 
tuberculosis topoisomerase I was also verified (Figure 2.7, B).  
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                                                    Table 2. T1. PCR primers for Gibson cloning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Gene Sequence (5’-3’) 
MsmTopoI_2OT_FP MsmtopA GGGATCGAGGAAAACCTGTACTTCCAAATG GCTGGCGGCGACCG 
MsmTopoI_2OT_RP MsmtopA GCGGATCCGTTATCCACTTCCAATATTGTTC GGCGGAAACCTAGGCCTTCTT 
RNA Polymerase 
beta_LIC_FP rpoB 
CTGTACTTCCAATCCAATGTGCTGGAAGG 
ATGCA 
RNA Polymerase 
beta_LIC_RP rpoB 
ATCCGTTATCCACTTCCAATCTACGCGAGA 
TCCTCGAC 
RNA Polymerase 
beta’_LIC_FP rpoC 
CTGTACTTCCAATCCAATGTGCTAGACGT 
CAACTTC 
RNA Polymerase 
beta’_LIC_RP rpoC 
CGTTATCCACTTCCAATTTAGCGGTAATCC 
GAGTAG 
Putative 
DEAD/DEAH_LIC_FP MSMEG_1930 
CTGTACTTCCAATCCAATATGACGCAACTCAATCACT 
CGTTTGC 
 
Putative 
DEAD/DEAH_LIC_RP MSMEG_1930 
CGTTATCCACTTCCAATTCAGCCTGCGGTGGCTGC 
 
Putative RhlE_LIC_FP RhlE 
CTGTACTTCCAATCCAATATGACCGCAGTGAAACAC 
ACAACTG 
 
Putative RhlE_LIC_RP RhlE CGTTATCCACTTCCAATTCAGTTAGCCCGCGCGGC  
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Purification of M. tuberculosis topoisomerase IgG from the Rabbit Serum 
The antibodies from the serum of a Rabbit were purified with Promega Protein A 
magnetic beads (G8781). In the Co-Immunoprecipitation assays, purified antibodies 
against topoisomerase I were used for precipitating the topoisomerase I complex from the 
lysate. A rabbit was injected with M. tuberculosis topoisomerase I (MtbTopoI), and the 
serum was collected for verification of the MtbTopoI IgG production. As a control, serum 
was also collected prior to the MtbTopoI injection. Western blots were performed to verify 
the antibodies in the serum. The serum, control and antibody containing, was used for 
isolation of IgG that will be later used in the Co-IP. The antibody purification protocol is 
detailed in chapter 3. The purified MtbTopoI IgG can cross-react with M. smegmatis 
topoisomerase I, MsmTopoI (Figure 3.3). 
 
Co-Immunoprecipitation (Co-IP)/ Tandem Mass spectrometry 
The complex of M. smegmatis topoisomerase I (MsmTopoI) and its potential 
protein partners were isolated from the M. smegmatis soluble cell lysate by Co-IP (Free et 
al., 2009).  M. smegmatis mc2 155 was grown to stationary phase in LB-Tween 80 (0.1%).  
The pelleted cells were resupsended in lysis/wash buffer (50 mM NaCl, 50 mM NaH2PO4, 
pH 8.0, 0.1% NP-40), and then subjected to 5 pulses of sonication (10 seconds/pulse at 
medium intensity). The lysate was spun at 16000xg for an hour, and the supernatant soluble 
lysate was used as prey in the Co-IP assays. The soluble lysate was pre-incubated (pre-
cleared) with protein A/G plus Agarose beads to remove proteins that bind non-specifically 
to the beads. The pre-cleared lysate (total protein=500 µg) was first mixed with IgG (10 
µg) purified from serum of a rabbit inoculated with MtbTopoI or control pre-immune 
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serum.  The rabbit MtbTopoI polyclonal antibodies can cross react with MsmTopoI (Figure 
3.3).   The Protein A/G plus agarose beads (Santa Cruz), previously equilibrated in wash 
buffer, were then added to the lysate-antibody reaction and left overnight at 4°C.  On the 
following day, the reaction mixture was spun at 700xg, and the supernatant was discarded. 
The bead pellet, with the bound proteins, was washed thrice in the wash buffer. The elution 
of the proteins bound to the beads was carried out by suspending the bead pellet in 4X SDS 
sample buffer (240 mM Tris-HCl, 8% SDS, 40% glycerol, 0.04% bromophenol blue), and 
heating at 95°C for 2 minutes. The eluted proteins (MsmTopoI, and its potential protein 
partners) were stained with coomassie blue following SDS PAGE.  The protein bands of 
interest were excised for characterization by tryptic digest and mass spectrometry (nano 
LC/MS/MS) at the Proteomics and Mass Spectrometry Facility of University of 
Massachusetts Medical School.  The MS/MS results were searched using Mascot (Matrix 
Science, London, UK; version 2.5.0) against the UniProt_MSmegmatis_071714 database 
for trypsin digestion products.  
 
Pull-down assay/ Tandem Mass spectrometry 
For the pull-down assay (Brymora et al., 2004), a high concentration of the target 
protein (MsmTopoI) with a fusion tag (N-terminal 6xHistidine) was mixed with M. 
smegmatis mc2 155 soluble cell extract for 2 hours at 4°C, and then immobilized on a 
HisPur Cobalt Agarose resin (Thermofisher). The resin with bound target proteins was 
washed thrice in a pull-down wash buffer (10 mM HEPES, pH 7.5, 10 mM Imidazole, 
0.005% Tween-20) to remove the weakly retained proteins.  The proteins that remained 
bound to the resin were eluted with pull-down elution buffer (10mM HEPES, pH 7.5, 350 
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mM Imidazole), separated by SDS PAGE and stained with coomassie blue.  The protein 
bands of interest were excised for identification by tryptic digest and nano LC/MS/MS.  
 
Physical interactions of Topoisomerase I with putative helicase, and RNA Polymerase 
RNA polymerase, and putative DEAD/DEAH box helicase were identified in the 
protein-protein interaction network of M. smegmatis topoisomerase I. However, the 
proteins may or may not be involved in direct physical interactions with topoisomerase I. 
The physical interactions, if any, between two proteins can be assayed by the incubation of 
proteins (as bait and prey) in the Pull-down (Banda et al., 2016). The fusion tag [6xHis-
Mocr] of purified prey protein was cleaved prior to their use in the assay (Phan et al., 2002). 
Briefly, the bait (His tagged putative helicase or RNA polymerase subunit) and the prey 
(MsmTopoI) were incubated together for 2 hours at 4°C. The bait-prey complex was 
trapped with HisPur cobalt resin, and washes were carried out with the pull-down wash 
buffer. The bait-prey complex was then eluted from the resin with the pull-down elution 
buffer. The eluate was resolved on a SDS-PAGE, and immunoblotted with antibodies 
against mycobacterial topoisomerase I.  
 
Helicase Assays 
The putative helicase identified as a protein partner of topoisomerase I has not been 
characterized before. The protein is believed to be a putative helicase based on the sequence 
homology with DEAD box helicase family of proteins. The purified putative helicase was 
tested for its DNA or RNA helicase activity. Synthetic oligonucleotides were ordered from 
Sigma for constructing the potential substrates of the putative helicase. A 5’ 32P labeled 
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DNA or RNA strand was created by incubating a synthetic oligonucleotide with T4 
polynucleotide kinase, and [g-32P]. The labeled oligonucleotide was heated at 95°C to 
inactivate the kinase. 3-fold excess of a complementary DNA or RNA was added, and 
allowed to anneal with labeled strand.  A 5’ over hang, 3’ over hang and blunt ended 
substrates were constructed for the verification of helicase activity. The helicase reaction 
mix (10 µl) contains 20 mM Tris-HCl; pH: 8.0, 5 mM MgCl2, 0.2 pmole of the radiolabeled 
substrate, and the putative helicase. The reaction was pre-incubated at room temperature 
for 10 minutes, before initiating the unwinding reaction with 3 mM ATP and a 10-fold 
excess of the unlabeled oligonucleotide (trap strand) identical to the labeled strand. The 
trap strand prevents the reannealing of the unwound strand to the labeled strand. The 
reaction was set up at 37°C for 45 minutes. The reaction was quenched with a buffer 
containing 1% SDS, 20 mM EDTA, 50% Glycerol, and 0.3% Bromophenol blue. The 
reaction products were electrophoresed on a 20% native polyacrylamide gel, and visualized 
by autoradiography (Uson et al., 2015).  
 
RESULTS 
Identification of RNA Polymerase, and putative helicases as protein-protein 
interaction partners of MsmTopoI 
Protein interaction network of the target protein (MsmTopoI) was analyzed by two 
different approaches: Co-IP, and Pull-down assays coupled to Mass spectrometry. The M. 
smegmatis topoisomerase I complex was isolated from M. smegmatis soluble lysate by 
either of the approaches, electrophoresed on a SDS polyacrylamide gel, and coomassie 
stained (Figure 2.2, B; Figure 2.3, B). The efficiency of the antibodies raised against 
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MtbTopoI to immunoprecipate MsmTopoI from the cell lysate was confirmed by western 
blot analysis of the Co-IP eluates (Figure 2.2, C). LC MS/MS analysis of the protein bands, 
a-d (Lane 5 of Figure 2. 2, B), identified M. smegmatis RNAP beta and beta’ subunits in 
protein band “a” and a putative helicase (MSMEG_2174) in the band “b”. Proteins 
involved in the metabolism of DNA, sugars, and lipids were also identified as protein 
partners by Co-IP (Table 2. T2). Alternatively, the potential protein partners of M. 
smegmatis topoisomerase I were also identified by analyzing the protein complexes pulled 
down with His-tagged MsmTopoI and MsmTopoI-CTD. Coomassie-stained proteins, e-f 
(lanes 7 and 8 of Figure 2.3, B), pulled down by either His-tagged MsmTopoI or 
MsmTopoI-CTD, but not control His-Mocr (lane 6, Figure 2.3, B) were analyzed by LC 
MS/MS.  M. smegmatis RNA polymerase beta and beta’ subunits were again identified in 
protein band “e”. Interestingly, Acetyl-/propionyl-coenzyme A carboxylase, a protein 
involved in the lipid metabolism was identified as potential partner of M. smegmatis 
topoisomerase I by both the Co-IP, and pull-down approaches. Helicase partners (Putative 
DEAD/DEAH Box helicase, ATP-dependent helicase HrpA, ATP dependent RNA 
helicase DeaD) were also identified by pull-down approach (Figure 2.3, B). However, it is 
essential to note that these helicase partners were not identified by the Co-IP approach.  
 
Physical interactions between RNA polymerase beta’ and Topoisomerase I 
There is a high degree of confidence, based on Co-IP and Pull-down (Figure 2.2, 
2.3), for the association of topoisomerase I with the RNA polymerase. However, the 
evidence for a physical interaction was not obtained from these experiments. The direct 
physical interactions were analyzed by purified recombinant proteins.  A Physical 
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interaction between M. smegmatis RNA polymerase beta’ subunit and M. smegmatis 
topoisomerase I was verified by both co-immunoprecipitation (Figure 3.6, A) and Pull-
down experiments (Figure 3.6, B).  This protein-protein interaction is specific.  No 
interaction with MsmTopoI could be observed for M. smegmatis RNA polymerase beta 
subunit (Figure 3.6, A). The physical interactions of topoisomerase I, and RNA polymerase 
beta’ subunit has shown species specificity. E. coli topoisomerase I was has not shown 
interactions with M. smegmatis RNA polymerase beta’ subunit (Figure 3.6, C).  
 
Physical interactions between DEAD/DEAH box helicase and Topoisomerase I  
Putative DEAD/DEAH Box helicase was identified in the protein interaction 
network of topoisomerase I by pull-down assays (Figure 2.3, band f). The putative helicase 
has a homologue, RhlE, in M. tuberculosis H37Rv. Topoisomerase I from M. tuberculosis 
H37Rv and M. smegmatis have a high degree of homology. Homology among these 
proteins can indicate a potential conservation of protein-protein interactions. Here, the 
physical interaction between the putative helicase and topoisomerase I of M. smegmatis, 
M. tuberculosis H37Rv was verified by pull-down assay. The assays have provided 
evidence for a physical interaction between putative helicase and topoisomerase I in M. 
smegmatis, M. tuberculosis (Figure 2.5) 
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Figure 2.2. Co-immunoprecipitation of topoisomerase I and interacting proteins from M. smegmatis lysate.  (A) Schematic of 
the Co-IP. (B) Proteins were stained with Coomassie blue following SDS-PAGE.  Lane 1: MW standards.  Lane 2: 15 µg of total 
M. smegmatis proteins in soluble lysate.  Lane 3: purified recombinant MsmTopoI.  Proteins were immunoprecipitated from M. 
smegmatis lysate (500 µg total proteins) by pre-immune rabbit antibodies (Lane 4) or antibodies raised against MtbTopoI (Lane 5).  
Bands a-d were selected for LC MS/MS analysis. (C) A fraction of the eluates from Co-IP reactions were electrophoresed on a SDS-
PAGE, and immunoblotted with TopoI antibodies. Lane 1: 25 ng of Purified MsmTopoI. The efficiency of the Co-IP assay was 
verified by analyzing a small fraction of eluates from the reaction of M. smegmatis lysate with pre-immune rabbit antibodies (Lane 
2), or antibodies raised against MtbTopoI (Lane 3). 
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Figure 2.3. Pull-down assay of MsmTopoI-RNAP interaction with HisPur Cobalt agarose resin. (A) General scheme of the 
Pull-down assay. (B) Proteins pulled down from M. smemgatis soluble lysate by recombinant N-terminal His-tagged MsmTopoI 
(Lane 8) or MsmTopoI-CTD (Lane 7).  His-Mocr, a recombinant viral protein, was used as a bait in the control reaction (Lane 6).  
Lane 1: MW standards; Lane 2: purified recombinant His-Mocr; Lane 3: purified recombinant His-MsmTopoI-CTD; Lane 4: purified 
recombinant His-MsmTopoI.   
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                              Table 2. T2. Potential protein partners of topoisomerase I identified by Co-IP/MS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band (Figure 1)          Proteins identified by MS/MS 
a 
1. RNA Polymerase beta (rpoB), 
2. RNA Polymerase beta’ (rpoC) 
3. Alpha-(1->3)-arabinofuranosyltransferase (aftD) 
b 
1. Putative helicase (MSMEG_2174) 
2. Glycoside hydrolase, family 3-like protein (MSMEG_5144) 
3. Phosphoribosyl formylglycinamidine synthase (purL) 
4. DNA translocase FtsK (MSMEG_2690) 
5. Drug exporters of the RND superfamily-like protein (mmpL3) 
c 
1. Uncharacterized protein (MSMEI_5149) 
2. Proteasome-associated ATPase (mpa) 
3. Transglycosylase (MSMEG_6201) 
d 
1. Serine/threonine-protein kinase (MSMEG_5513) 
2. Acetyl-/propionyl-coenzyme A carboxylase alpha chain (MSMEG_0334) 
3. Acetyl-/propionyl-coenzyme A carboxylase alpha chain (accA2) 
4. Succinate dehydrogenase flavoprotein (MSMEG_0418) 
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                                Table 2. T3. Potential protein partners of topoisomerase I identified by Pull-down/MS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band (Figure 2) Proteins identified by MS/MS 
e 
1. RNA Polymerase beta (rpoB) 
2. RNA Polymerase beta’ (rpoC) 
3. ATP-dependent helicase HrpA (MSMEI_6410) 
f 
1. DEAD/DEAH box Helicase (MSMEG_1930) 
2. Dihydroxyacetone kinase (MSMEG_3271) 
3. Pyruvate dehydrogenase (MSMEG_2280) 
4. Transcriptional regulator (MSMEI_6320) 
5. Propionyl coA carboxylase beta chain (accD5) 
6. Oxoalyl coA decarboxylase (oxcA) 
7. ABC Transporter ATP-binding protein (MSMEG_3140) 
8. Phosphoenolpyruvate-protein phosphotransferase (ptsI) 
9. Phosphoglucomutase/Phosphomannomutase (pmmB) 
10. RelA/Spot domain protein (MSMEG_5849) 
11. ATP-dependent RNA helicase DeaD (deaD) 
12. Acetyl-/propionyl-coenzyme A carboxylase alpha chain (MSMEG_0334) 
13. Fatty-acid-CoA ligase FadD6 (FadD6) 
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                         Figure 2.4. Unique peptides of RNAP subunits (highlighted) identified by mass spectrometry 
                         of the eluates from the Co-IP assay. 
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Figure 2.5. Physical interaction of putative DEAD/DEAH Box helicase with topoisomerase I. (A) Pull-down: M. smegmatis 
topoisomerase I, MsmTopoI, can directly interact with putative DEAD/DEAH Box helicase (Lane 4,5,6). MsmTopoI did not by 
itself bind to the resin (Negative control, lane 7&8). (B) Pull-down: M. tuberculosis topoisomerase I, MtbTopoI, can directly interact 
with putative helicase, RhlE (Lane 2,3,4). Lanes 5&6: negative control. 
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Figure 2.6. Putative helicase, RhlE, has a 3’-5’ DNA helicase activity. Products from the helicase assays were electrophoresed 
on a 20% polyacrylamide gel. (A) Helicase activity was verified with a DNA substrate having a 3’ overhang. Lane 1: The product 
of incubating the substrate with the reaction mix (No enzyme). Lane 2: Product from heating the substrate at 95°C for 15 minutes. 
Lane 3-7: Products of substrate incubation with the indicated amounts of putative helicase. (B) Verification of the helicase activity 
on a substrate with 5’ overhang. Lane 1: Product of substrate incubated with the reaction mix (No enzyme). Lane 2: The product of 
the substrate heated at 95°C for 15 minutes. Lanes 3, 4: The products from the treatment of substrate with the indicated amounts of 
putative helicase. 
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Figure 2.7.  Putative helicase –RhlE and M. tuberculosis topoisomerase I (MtbTopoI) have a mutual inhibitory effect on their 
activities. (A) Helicase assays were carried out in the presence and absence of MtbTopoI. A 3’-overhang DNA substrate was used. 
Products from the assays were electrophoresed on a 20% native polyacrylamide gel. Lane 1: Product of incubating DNA substrate 
with the reaction mix (No putative helicase); Lane: Product of heating the DNA substrate at 95°C for 15 minutes; Lanes 3-5: Products 
of incubating the substrate with the indicated amounts of putative helicase; Lane 6,7: Product of incubating the substrate with the 
indicated amounts of putative helicase and topoisomerase I; Lane 8: Product of incubating the substrate with the indicated amount 
of topoisomerase I (B) Relaxation activity of MtbTopoI was verified in the presence and absence of the putative helicase. Lane 1: 
Supercoiled DNA; Lane 2: Product of incubating supercoiled DNA with the indicated amount of MtbTopoI; Lane 2-6: Product of 
incubating supercoiled DNA with the indicated amounts of MtbTopoI and RhlE; Lane 7: Product of incubating supercoiled DNA 
with the indicated amount of RhlE. 
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Putative helicase, RhlE, has a 3’-5’ DNA helicase activity 
The DEAD/DEAH Box helicase of M. smegmatis, and RhlE of M. tuberculosis are 
putative helicases. Their helicase activity has not been verified before, and they have been 
considered as putative helicases because of the helicase motifs in their amino acid 
sequence. Helicase assays, in the presence of ATP and Mg (II), were carried out to verify 
the helicase activities. While RhlE has shown a 3’- 5’ DNA helicase activity (Figure 2.6), 
its homologue (DEAD/DEAH Box helicase of M. smegmatis) did not show this activity 
under similar experimental conditions. RhlE also did not show any helicase activity on a 
DNA substrate with blunt ends or a 5’ over hang. Assays were performed to verify the 
influence of topoisomerase I on the helicase activity, and vice versa. The results suggested 
a mutual inhibition of their activities (Figure 2.7). However, it could most likely be possible 
that the mutual inhibitory effect of the enzymes is the result of a competition for binding 
the DNA substrate. 
 
DISCUSSION 
The protein-protein interactions of M. smegmatis topoisomerase I were studied by 
two approaches; Co-IP, and pull-down assays coupled to mass spectrometry (Brymora et 
al., 2004; Free et al., 2009). We anticipated identification of similar protein partners with 
either of these approaches. However, the mass spectrometry data revealed almost entirely 
different partners for topoisomerase I, depending on the approach (Tables 2. T2, 2. T3). 
The dynamic nature of protein-protein interactions, and the vigorous washing steps 
involved with these assays could have played a part here. Interestingly, RNA polymerase 
beta and beta’ subunits were identified as potential partners by both the approaches, giving 
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us a higher confidence in the interaction of RNA polymerase with topoisomerase I. The 
physical interaction between RNAP and topoisomerase I was reported in E. coli (Cheng et 
al., 2003), and evidence provided here verified the conservation of this interaction in 
mycobacteria. The pull-down approach (Lane 7 of Figure 2.3, B: band e) coupled to mass 
spectrometry has suggested that the C-terminal domain of MsmTopoI can interact with 
RNA polymerase by itself. E. coli topoisomerase I requires tetracysteine zinc ribbon motifs 
for interaction with RNAP beta’ subunit. Since mycobacterial topoisomerase I lacks the 
tetracysteine motifs, a novel mechanism of interaction was predicted. The mechanism, and 
physiological relevance of the RNAP-topoisomerase I interaction is reported in greater 
detail in chapter 3. 
Apart from RNAP, proteins involved in the metabolism of DNA, sugars, and lipids 
were among the identified partners. The association of topoisomerases with helicases could 
have a physiological significance, as the interaction could assist in the progression of 
replication fork, chromosome segregation, recombination, repair and genomic stability 
(Duguet, 1997). Evolutionarily conserved RecQ helicases have a functional association 
with type IA topoisomerases (Mankouri and Hickson, 2007; Vindigni and Hickson, 2009). 
In yeast, RecQ helicases and topoisomerase III have a physical and functional interaction 
(Gangloff et al., 1994, Ellis et al., 1995). In humans, topoisomerase IIIα is recruited by a 
RecQ helicase, BLM, to resolve the non-canonical DNA structures (Double holliday 
junctions, D-loops, G-quadruplexes) in cells (Wu and Hickson, 2003; Hu et al., 2001; Wu 
et al., 2000; Johnson et al., 2000). The human topoisomerase IIIα	–	BLM complex also 
contained a third protein, RMI1 (Hoatlin et al., 2005). The association of topoisomerase 
IIIα-BLM-RMI1 is essential for the maintenance of genomic integrity (Chang et al., 2005; 
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Mullen et al., 2005). Like topoisomerase IIIα, the physical and functional association of 
topoisomerase IIIβ have also been identified. The proposed role of topoisomerase IIIβ in 
resolving the R-loops formed during the transcription process, as a partner in a complex 
containing a tudor-domain containing protein (TDRD3) further implicates the role of 
topoisomerase interactions in genomic maintenance (Yang et al., 2014).   
With the Co-IP and pull- down assays, identification of novel helicases and recently 
identified partners of M. smegmatis topoisomerase I: 3-Methyladenine DNA glycosylase 
(Yang et al., 2012), and D-ribokinase (Yang et al., 2011) was anticipated as possibilities. 
Since the Co-IP assays were performed with antibodies that were not cross-linked to beads, 
the denatured eluates of the assay were expected to have the light and heavy chains of the 
IgG along with the potential protein partners. The IgG bands in the coomassie stained gel 
have hindered identification of protein partners, 3-Methyladenine DNA glycosylase and 
D-ribokinase, which are in the same molecular weight range. Similarly, pull-down assay 
(Figure 2.3) was problematic in the analysis of protein partners of lower molecular weight 
due to very high non-specific binding of a number of proteins to the beads, as evident from 
the control experiment. Novel helicases (Putative DEAD/DEAH Box helicase, ATP-
dependent helicase HrpA, ATP-dependent RNA helicase deaD, putative helicase 
MSMEG_2174) were identified as partners of M. smegmatis topoisomerase I. In the future, 
it will be interesting to study the physiological relevance of helicase-topoisomerase I 
interactions in the survival of mycobacteria.   
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CHAPTER 3 
EVOLUTION OF A NOVEL MECHANISM FOR MYCOBACTERIAL RNA 
POLYMERASE AND TOPOISOMERASE I INTERACTION 
 
ABSTRACT 
 
Protein-protein interactions are the key elements of cellular processes including 
DNA replication, transcription, recombination and repair. In this study, we report a novel 
mechanism of interaction between topoisomerase I, and DNA-dependent RNA polymerase 
in Mycobacterium tuberculosis and Mycobacteria smegmatis. Bacterial DNA 
topoisomerase I is responsible for preventing the hyper-negative supercoiling of genomic 
DNA.  The association of topoisomerase I with RNA polymerase during transcription 
elongation could efficiently relieve transcription driven negative supercoiling.  Our results 
demonstrate a direct physical interaction between the C-terminal domains of topoisomerase 
I (TopoI-CTD) and the beta’ subunit of RNA polymerase of M. tuberculosis and M. 
smegmatis in the absence of DNA.  The TopoI-CTD in mycobacteria are evolutionarily 
unrelated in amino acid sequence and 3-dimensional structure to the TopoI-CTD found in 
the majority of bacterial species outside Actinobacteria, including Escherichia coli.  The 
functional interaction between topoisomerase I and RNA polymerase has evolved 
independently in mycobacteria and E. coli, with distinctively different structural elements 
of TopoI-CTD being utilized for protein-protein interaction.   Instead of zinc ribbon motifs 
seen for E. coli topoisomerase I, the 27 amino acid tail rich in basic residues at the C-
terminal end of M. smegmatis topoisomerase I is responsible for the interaction with RNA 
polymerase.  Overexpression of the TopoI-CTD as a recombinant protein in M. smegmatis 
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competed with TopoI for protein-protein interaction with RNA polymerase.  The TopoI-
CTD overexpression resulted in a decreased survival following treatment with antibiotics 
and hydrogen peroxide, supporting the importance of the protein-protein interaction 
between topoisomerase I and RNA polymerase during stress response of mycobacteria.   
 
INTRODUCTION 
Topoisomerases are essential enzymes responsible for control of DNA topology 
and facilitating vital cellular processes that include replication, transcription, 
recombination and DNA repair (Vos et al., 2011; Chen et al., 2013).  The active site for 
DNA cleavage and rejoining by type IA topoisomerases is evolutionarily conserved at the 
N-terminal domains of bacterial topoisomerase I and topoisomerase III (Baker et al., 2009).   
Bacterial topoisomerase I is responsible for relieving the transcription driven negative 
supercoiling, generated behind the RNA polymerase complex during transcription 
elongation (Liu et al., 1987; Wu et al., 1988; Masse et al., 1999a). The absence of 
topoisomerase I activity in Eshcherichia coli has been shown to result in increased R-loop 
formation via the stable association of the nascent transcript with the unwound DNA 
(Drolet et al., 1995; Masse et al., 1999b). This could potentially block transcription 
elongation (Hraiky et al., 2000). A direct association between RNA polymerase and 
topoisomerase I would facilitate gene expression at highly transcribed loci, including genes 
induced for survival in stress response.   
It was previously reported that E. coli RNA polymerase beta’ subunit interacts 
directly with the zinc ribbon and zinc ribbon-like C-terminal domains (CTD) of 
topoisomerase I (Cheng et al., 2003; Tiwari et al., 2016). In E. coli and most bacterial 
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species, the CTD of topoisomerase I have multiple zinc ribbon domains, each with a Zn(II) 
ion coordinated by four cysteines (Tse-Dinh et al., 1988; Suerbaum et al., 1998; Grishin, 
2000).  In contrast, the topoisomerase I proteins in Acintobacteria, including mycobacteria, 
evolved with TopoI-CTD that do not have zinc ribbon or zinc ribbon-like domains (Ahmed 
et al., 2013). Structural determination by X-ray crystallography showed that the 
Mycobacterium tuberculosis topoisomerase I CTD are formed by repeats of a novel protein 
fold of a four-stranded antiparallel β-sheet stabilized by a crossing-over α-helix (Tan et al., 
2016).   
We speculated that the CTD of Mycobacterial topoisomerase I could be involved 
in protein-protein interactions, among its other functions.  The protein-protein interactions 
of topoisomerase I from M. smegmatis were studied by co-immunoprecipitation (Co-IP), 
and pull-down assays coupled to tandem mass spectrometry (Brymora et al., 2004; Free et 
al., 2009). The assays identified an interaction between DNA-dependent RNA polymerase 
(RNAP), and topoisomerase I in M. smegmatis.  This TopoI-RNAP interaction also 
employed the CTD of topoisomerase I even though the mycobacterial topoisomerase I 
CTD do not have zinc ribbon. The conservation of this interaction in M. tuberculosis with 
a novel mechanism of protein-protein interaction was verified with further studies here. 
 
MATERIALS AND METHODS 
Bacterial strains, plasmids, and cloning 
M. smegmatis mc2 155 was obtained from ATCC and cultured in 7H9 broth or LB-
Tween 80 (0.1%). M. tuberculosis H37Rv genomic DNA and whole cell lysates were 
obtained from BEI resources. A plasmid, pMsmTopoI, for overexpression of 
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topoisomerase I in M. smegmatis was constructed by placing M. smegmatis topA coding 
sequence (amplified with primers shown in Table 3. T2) under the control of the 
tetracycline inducible TetRO promoter in pKW08 vector (Williams et al., 2010) via Gibson 
assembly cloning (Gibson, 2011).  Plasmid pMsmTopoI-CTD was then constructed for 
overexpression of the C-terminal domains D5-D8 plus tail (residues 627-936) by deleting 
the N-terminal domains D1-D4 (residues 1-626) via site-directed mutagenesis.   
Overexpression of M. smegmatis topoisomerase I (MsmTopoI) in E. coli BL21 STAR DE3 
(Invitrogen) was achieved by Gibson cloning MsmtopA gene into pET His6 Mocr TEV 
LIC cloning vector (2O-T, Addgene Plasmid# 29710). The vector was later used for 
constructing various subdomains of topoisomerase I via site directed mutagenesis (Table 
3. T3). Cloning of recombinant M. tuberculosis topoisomerase I (MtbTopoI) and its CTD 
in vector pLIC-HK (Doyle, 2005) for expression in E. coli BL21- CodonPlus(DE3)-RP 
(Agilent) was described previously (Annamalai et al., 2009). M. smegmatis RNAP beta 
(RpoB) and beta’ (RpoC) subunits were inserted by Gibson cloning into the SspI site of 
pLIC-HK, and transformed into E. coli SoluBL21 (Genlantis) cells for protein expression 
and purification. The PCR primers used in the cloning, and site-directed mutagenesis are 
listed in the Tables 3. T2 and 3. T3.
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                                                                  Table 3. T1. Strains used in this study 
 
Strain Description Source 
MS_WT Wild type M. smegmatis mc2 155 ATCC 
H37Rv M. tuberculosis ATCC 
MS_CTD TopA 
M. smegmatis transformed with a vector pKW08_CTD TopA. This strain 
over-expresses the C-terminal domain of topoisomerase I, upon induction 
with tetracycline. Western blots have confirmed that the over-expression is 
tightly regulated. 
This study 
MS_NOLUX M. smegmatis transformed with a vector pKW08. This strain was used as a control in the in vivo stress experiments. 
Williams et 
al., 2010 
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                                                     Table 3. T2. PCR primers for Gibson cloning  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Gene Sequence (5’-3’) 
RNA Polymerase 
beta_LIC_FP rpoB 
CTGTACTTCCAATCCAATGTGCTGGAAGG 
ATGCA 
RNA Polymerase 
beta_LIC_RP rpoB 
ATCCGTTATCCACTTCCAATCTACGCGAGA 
TCCTCGAC 
RNA Polymerase 
beta’_LIC_FP rpoC 
CTGTACTTCCAATCCAATGTGCTAGACGT 
CAACTTC 
RNA Polymerase 
beta’_LIC_RP rpoC 
CGTTATCCACTTCCAATTTAGCGGTAATCC 
GAGTAG 
MsmTopoI_pKW08_FP MsmtopA TTCGCGGATCCTTGGCTGGCGGCG ACCGCGG 
MsmTopoI_pKW08_RP MsmtopA TTCTCAAGCTTCTAGGCCTTC TTGGCGGCGG 
MsmTopoI_2OT_FP MsmtopA GGGATCGAGGAAAACCTGTACTTCCAAATG GCTGGCGGCGACCG 
MsmTopoI_2OT_RP MsmtopA GCGGATCCGTTATCCACTTCCAATATTGTTC GGCGGAAACCTAGGCCTTCTT 
D1-D8_MsmTopoI_2OT_FP D1-D8 MsmtopA 
GGGATCGAGGAAAACCTGTACTTCCAAATG 
GCTGGCGGCGACCG 
D1-D8_MsmTopoI_2OT_RP D1-D8 MsmtopA 
GCGGATCCGTTATCCACTTCCAATATTGTTA 
GGCACGGCGGTCGG 
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                                                  Table 3. T3. Primers used for Site-Directed Mutagenesis 
 
 
 
 
 
 
 
 
 
 
Primers for Site-Directed Mutagenesis 
Primer Sequence (5’-3’) Description 
CTD-MsmTopoI_ pKW08_FP GGATCCTGTCAGGATTCCACGATGAGAG  Deletion of the N-terminal domain from the full length MsmTopA 
gene, that was previously cloned into pKW08. CTD-MsmTopoI_ pKW08_RP GGCGTCGAGGGTTCGATCGCG 
NTD-MsmTopoI_2OT_FP TAGAACCTCGAAGGCATCGACGC 
 
Insertion of a stop codon in the MsmtopA gene for early termination at 
the end of the N-terminus. 
 NTD-MsmTopoI_2OT_RP GCCGCCGACGAGCTGCTT 
D1-D5_MsmTopoI_2OT_FP GCGTCCCTCTTGCTATGTGGCGAAGAGCTTTTCGG   
 
The proline (702) of MsmtopoI was substituted with a stop codon. The 
resulting protein (1-701) is termed as D1-D5. D1-D5_MsmTopoI_2OT_RP 
 
CCGAAAAGCTCTTCGCCACA
TAGCAAGAGGGACGC 
 
D1-D6_MsmTopoI_2OT_FP 
 
GCCCACGACGCGCTACAGCG
ACAGCAGC 
 
 
 
 
The proline (786) of MsmtopoI was substituted with a stop codon. The 
resulting protein (1-785) is termed as D1-D6. D1-D6_MsmTopoI_2OT_RP 
 
GCTGCTGTCGCTGTAGCGCG
TCGTGGGC 
 
D1-D7_MsmTopoI_2OT_FP 
 
CGGCCACGGCGTTTCTACTC
GGCGTAGATCTT 
 The proline (840) of MsmtopoI was substituted with a stop codon. The 
resulting protein (1-840) is termed as D1-D7. 
D1-D7_MsmTopoI_2OT_RP 
 
AAGATCTACGCCGAGTAGAA
ACGCCGTGGCCG 
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Protein expression and purification 
DNA topoisomerase I, sub-domains of topoisomerase I, RNAP beta, and RNAP 
beta’ subunits were purified as recombinant proteins for protein-protein interaction studies. 
Overexpression of these recombinant proteins in the E. coli hosts was induced with 1 mM 
IPTG. Following the overexpression and cell lysis, recombinant proteins were purified to 
near homogeneity by affinity chromatography using Ni-Sepharose 6 Fast flow beads (GE 
Healthcare Life Sciences) followed by size-exclusion chromatography.  
Affinity Chromatography:  The MsmTopoI over expression clone, BL21 AI-
2OT-MsmTopA, is cultured to exponential phase of growth in LB-NaCl (0.5 M) medium. 
At the exponential phase, the cells were induced with 1mM IPTG, 0.2% L-Arabinose at 
20°C for 12 hours. The cell culture was pelleted, and the cells were lysed by freeze-thaw 
cycles. The whole cell lysate was spun at 32000 rpm for 2 hours, and the supernatant 
soluble protein fraction was passed through Ni+2-Sepharose fast flow column for the 
purification of the hexa-histidine tagged topoisomerase I. A wash buffer (50 mM NaH2PO4, 
300 mM NaCl, 20 mM imidazole; pH: 8.0) was passed along the column to remove any 
non-specifically bound proteins. A gradient elution method was followed to elute the 
recombinant proteins bound to the column. The elution buffer has imidazole concentrations 
ranging from 20 mM - 400 mM. The eluate fractions having the desired protein was 
dialyzed into 20 mM KH2PO4, 1 mM EDTA, 0.1 M KCl, 10% Glycerol.  
TEV Protease reaction (Fusion tag removal): The recombinant protein was 
treated with the TEV protease for the removal of the purification handle (6xHis-Mocr tag) 
(Phan et al., 2002) . 1 part of TEV protease, a highly sequence-specific cysteine protease 
from Tobbaco Etch Virus, and 25 parts of the recombinant protein (6xHis-Mocr-
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MsmTopoI) were incubated together at 20°C for 4 hours initially, and then at 4°C 
overnight. The reaction mixture contains 50 mM Tris (pH: 8.0), 0.5 mM EDTA, and 1 mM 
DTT. The TEV protease reaction product was passed through the Ni+2-Sepharose column, 
and the flow-through (MsmtopoI, devoid of tag) is collected. The elutions from the column 
were made with 400 mM imidazole containing phosphate buffer.  
Gel-Filtration (Size Exclusion Chromatography): The flow-through from the 
TEV-protease reaction, the recombinant protein devoid of the tag, was passed through a 
gel-filtration column for a separation based on the size. A HiPrep 26/60 Sephacryl S-
200HR column (GE Healthcare) was equilibrated with degassed Tris buffer (20 mM Tris; 
pH: 8.0, 0.3 M KCl). The sample (load) was passed through the column, and washes were 
carried out with Tris buffer. The eluate fractions containing the desired protein were 
pooled, and dialyzed into storage buffer (0.1 M KH2PO4, 0.2 mM EDTA, 0.2 mM DTT, 
50% Glycerol). A similar approach was followed in the purification of all the other proteins 
that were a part of this study. 
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Figure 3.1. Protein (M. smegmatis topoisomerase I) purification; (A) Protein over-expression was confirmed. Lane 2, represents 
the whole cell lysate of BL21 AI-2OT-MsmTopA before the protein over-expression. Lane 3, represents the soluble protein fraction 
from the cells subjected to protein over-expression.  (B) The eluates from the Ni+2-Sepharose column. (C) The recombinant tag was 
removed by the TEV protease reaction. (D) The eluate fractions from the Gel filtration column were electrophoresed on a SDS-
PAGE, and coomassie stained. 
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Figure 3.2.  Relaxation activity of the purified topoisomerase I; The assay successfully demonstrates the relaxation of the 
negatively supercoiled DNA in the presence of the enzyme (Lane 2-8).  
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                                                          Table 3. T4. Recombinant Proteins used in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. T4 contains a comprehensive list of proteins that were expressed, and purified for this study. Mocr, a fusion tag, enhances 
the solubility of the recombinant protein (DelProposto et al., 2009). 
 
 
Protein Organism Cloning vector 
Cleavable fusion tag 
(TEV Site) 
Recombinant 
Tag (N-terminal) 
Topoisomerase I 
(1-936 Amino acids) M. smegmatis 2O-T Yes 6xHis-Mocr 
Topoisomerase I 
(1-934 Amino acids) M. tuberculosis 2O-T Yes 6xHis-Mocr 
Topoisomerase I 
(D1-D8) 
(1-910 Amino acids) 
M. smegmatis 2O-T Yes 6xHis-Mocr 
Topoisomerase I 
(D1-D7) 
(1-840 Amino acids) 
M. smegmatis 2O-T Yes 6xHis-Mocr 
Topoisomerase I 
(D1-D6) 
(1-786) 
M. smegmatis 2O-T Yes 6xHis-Mocr 
Topoisomerase I 
(D1-D5) 
(1-701 Amino acids) 
M. smegmatis 2O-T Yes 6xHis-Mocr 
Topoisomerase I 
(D1-D4); N-terminal 
(1-626 Amino acids) 
M. smegmatis 2O-T Yes 6xHis-Mocr 
Topoisomerase I 
(C-terminal) 
(657-936 Amino acids) 
M. smegmatis 2O-T No 6xHis 
RNA Polymerase beta’ M. smegmatis LIC-HK Yes 6xHis 
RNA Polymerase beta M. smegmatis LIC-HK Yes 6xHis 
 86 
Purification of M. tuberculosis topoisomerase IgG from the Rabbit Serum 
Purified antibodies were used in the Co-Immunoprecipitation (Co-IP) assays. The 
antibodies were purified from the Rabbit serum obtained before and after injection with M. 
tuberculosis topoisomerase I (MtbTopoI). Antibody (IgG) purification was carried out 
using Promega Protein A magnetic beads (G8781), according to the manufacturer’s 
protocol. Briefly, 100µl of protein A beads were initially equilibrated in wash buffer (8.1 
mM Na2HPO4, 1.47 mM KH2PO4, 137 mM NaCl, 2.68 mM KCl; pH: 7.4), and incubated 
with 250 µl of the serum for 4 hours at 4°C. Magnetic field was applied by placing the 
reaction tubes in a Magnetic separation stand. The unbound components of the serum 
(supernatant) were carefully removed, and the bead pellet was washed thrice in the wash 
buffer. Finally, the bead pellet was eluted with 150µl of 100 mM Glycine-HCl (pH: 2.7), 
and the eluate was neutralized by mixing with 30 µl of 2 M Tris buffer (pH: 7.5). The 
concentrations of the pure antibodies were verified based on a colorimetric, Bradford dye-
binding method (Bio-Rad Protein Assay Kit; 5000006). 
 
 
 
 
 
Figure 3.3. Cross-reactivity of Rabbit MtbTopoI polyclonal antibodies with 
MsmTopoI; Rabbit Polyclonal antibodies that were generated against MtbTopoI can 
cross-react with MsmTopoI due to a high sequence homology between these proteins. 
Western blotting of the soluble lysates from M. smegmatis mc2 155 was carried out to verify 
the cross-reactivity of the antibody. Lane 1: Soluble lysate (10 µg) from H37Rv. Lane 2-
4: Purified MtbTopoI (25 ng, 50 ng, 75 ng). Lane 5: Purified MsmTopoI (25 ng). Lane 6-
8: Soluble lysates (10 µg) of M. smegmatis mc2 155 over the course of its growth (Lane 6: 
OD600- 0.8, Lane 7: OD600- 1.5, Lane 8: OD600- 3.0). 
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Co-Immunoprecipitation (Co-IP)/ Tandem Mass spectrometry 
The protein networking of M. smegmatis topoisomerase I was analyzed by Co-
Immunoprecipitation coupled to tandem mass spectrometry (Free et al., 2009). Briefly, 
stationary phase M. smegmatis mc2 155 pellet was suspended in a lysis/wash buffer (50mM 
NaCl, 50 mM NaH2PO4, pH 8.0, 0.1% NP-40), and then subjected to sonication (ultrasound 
energy) for releasing the cellular contents. The lysate centrifuged at 16000xg for an hour, 
and the supernatant soluble lysate was used as prey in the Co-IP assays. Protein A/G plus 
agarose beads (Santa Cruz) were used for the Co-IP assays. Each Co-IP reaction contained 
500 µg of the total soluble protein, 10 µg of the purified antibody, and the Protein A/G plus 
agarose beads. The eluates from the reaction were subjected to SDS-PAGE electrophoresis, 
and the resolved protein bands were excised for characterization of the proteins by mass 
spectrometry. A detailed protocol is provided in Chapter 2.  
 
Pull-down assay/ Tandem Mass spectrometry 
The protein networking of M. smegmatis topoisomerase I was also verified by a 
Pull-down approach coupled with Mass spectrometry (Brymora et al., 2004). In this 
approach, the target protein was used in concentrations higher than usually found in the 
physiological conditions. High concentration of target protein, recombinant MsmTopoI 
(N-terminal 6xHistidine tagged), is incubated with M. smegmatis mc2 155 soluble cell 
extract for 2 hours at 4°C, and later immobilized on a HisPur Cobalt Agarose resin 
(Thermofisher). The wash, elution, SDS-PAGE electrophoresis, and analysis by mass 
spectrometry is described in detail in chapter 2. 
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Reverse Pull-down assay/ Immunoblotting 
A reverse pull-down assay was used to validate the protein interactions identified 
by pull-down assay. In this assay, a recombinant M. smegmatis RNAP beta’ subunit (N-
terminal 6xHistdine) was used as a bait to pull-down topoisomerase I from the soluble cell 
extract. The Pull-down protocol is similar that described in the previous section.  Western 
blot analysis with rabbit polyclonal antibodies against MtbTopoI was used to detect the 
presence of topoisomerase I in the eluate.  
 
Pull-down, Co-IP assays on M. tuberculosis (H37Rv) cell extract 
The conservation of RNA Polymerase-topoisomerase I protein-protein interactions 
in M. tuberculosis was verified by pull-down, and Co-IP assays. Whole cell extract of M. 
tuberculosis H37Rv was provided by BEI Resources. The extract was spun at 16000xg for 
20 min at 4oC, and the soluble protein fraction was used for the assays. Recombinant 
MtbTopoI with N-terminal 6x-Histidine was used in the pull-down assay, while antibody 
against topoisomerase I was used in the Co-IP assay as a bait to determine if RNA 
polymerase could be captured from the cell extract.  Following SDS PAGE, the proteins in 
the eluates from the assays were immunoblotted with a monoclonal antibody against RNA 
Polymerase beta (Biolegend) which can recognize the RNAP beta subunits (Bergendahl et 
al., 2003) across multiple species including M. tuberculosis and M. smegmatis. 
 
Physical interactions between RNA Polymerase beta’ subunit and Topoisomerase I 
The use of cell extract, as prey, in the pull-down and Co-IP assays can only provide 
information on the protein networking of a target protein. The physical interactions, if any, 
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between two proteins can be studied by use of pure proteins (as bait and prey) in the pull-
down (Banda et al., 2016), and Co-IP assays. Isothermal Calorimetry, Surface Plasmon 
Resonance could be used for obtaining the kinetic parameters of the physical interaction 
between proteins (Pierce et al., 1999; Tiwari et al., 2016). However, these methods require 
large amounts of protein, and are expensive. Hence, the physical interactions between 
topoisomerase I, and RNA polymerase b,b’ subunits were studied by minor modifications 
of pull-down, and Co-IP assays. The fusion tag [6xHis or 6xHis-mocr] of purified prey 
proteins was cleaved prior to their use in the assay (Phan et al., 2002). 
 
Effect of M. smegmatis TopoI-CTD overexpression on sensitivity to antibiotics or 
hydrogen peroxide  
M. smegmatis strain over expressing the CTD of topoisomerase I from plasmid 
pMsmTopA-CTD, or a control M. smegmatis strain transformed with the cloning vector, 
were cultured to stationary phase in 7H9 medium containing Hygromycin (100µg/ml), and 
Tetracycline (25ng/ml). The cultures were adjusted to OD600=1.0 in 7H9 medium, and 
200µl of the OD adjusted culture was spread on a LB plate.  Antibiotic or H2O2 was applied 
to paper discs placed at the center of the plates, followed by incubation at 37°C for 60 hrs. 
The diameter of the zone of inhibition was measured. For comparison of viable colony 
counts following stress challenge, the M. smegmatis strains were grown in Luria broth-
Tween 80 (0.1%) containing Hygromycin (100µg/ml) and Tetracycline (25ng/ml). At 
exponential phase, the cultures were treated with Moxifloxacin (0.5 µM or 1 µM) for 12 
hours at 37°C. The treated cultures, and untreated cultures were serially diluted, and plated 
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on LB-Agar. The viable colonies were counted, and the relative viability ratio (treated 
versus untreated) was calculated. Similarly, viable colony counts following treatment with 
hydrogen peroxide (10 mM or 20 mM) was analyzed with the strains cultured in 7H9 
medium containing Hygromycin (100 µg/ml), and Tetracycline (25 ng/ml).   
 
RESULTS 
 
Identification of RNA Polymerase as protein-protein interaction partner of 
MsmTopoI 
Protein interaction network of the target protein (MsmTopoI) was first analyzed by 
Co-IP (Figure 2.2) coupled to Mass spectrometry. Following SDS-PAGE of the 
immunopreciptated proteins, coomassie-stained proteins in the bands, labeled as a-d (lane 
5 of figure 2.2, B), were selected as M. smegmatis proteins co-immunopreciptated by 
MtbTopoI antibodies that can also recognize MsmTopoI (Figure 3.3). The control purified 
pre-immune antibodies did not precipitate any proteins corresponding to the bands a-d, as 
evident from the coomassie stain (Lane 4 of figure 2.2, B). LC-MS/MS for identification 
of proteins in the bands, a-d, of the MtbTopoI Co-IP reaction and the corresponding bands 
in the control reaction was carried out.  A comprehensive list of proteins precipitated by 
MtbTopoI IgG alone, and not the control pre-immune IgG is provided in the table 2. T2. 
The ability of the antibodies raised against MtbTopoI to immunoprecipitate MsmTopoI 
from the cell lysate was confirmed by western blot analysis of the Co-IP eluates (Figure 
2.2, C).  LC MS/MS analysis identified M. smegmatis RNAP beta and beta’ subunits in the 
protein band “a”.     
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Protein networking of MsmTopoI was further investigated by Pull-down assay as 
described in Figure 2.3, A with His-tagged MsmTopoI and MsmTopoI-CTD. Coomassie-
stained proteins (e, f in lanes 7 and 8 of Figure 2.3, B) of M. smegmatis pulled down by 
either His-tagged MsmTopoI or MsmTopoI-CTD, but not control His-Mocr (lane 6, Figure 
2.3, B) were analyzed by LC MS/MS.  M. smegmatis RNA polymerase beta and beta’ 
subunits were again identified in protein band “e”.  
 
 
 
 
 
 
 
 
 
Figure 3.4. Reverse pull-down of MsmTopoI from M. smegmatis soluble lysate with 
purified recombinant RNA polymerase β’ subunit (N-terminal His-tagged). Following 
SDS PAGE, the proteins eluted from the HisPur Cobalt were analyzed by Western blot 
using anti-topoisomerase I antibodies.  Lane 1: purified recombinant MsmTopo I (100 ng).  
Lane 2: 15 µg of total proteins in M. smegmatis soluble lysate.  Lanes 3-6: Eluates from 
Pull-down assay using 500 µg of total proteins in M. smegmatis soluble lysate with His-
tagged RNAP β’ subunit of concentrations 100nM (Lane 3), 50 nM (Lane 4), 10 nM (Lane 
5); 0 nM (Lane 6).  The nitrocellulose membrane was also stained with Ponceau S for 
detection of the recombinant bait (His-tagged RNAP β’) used in the assay. 
 
Protein-protein interaction between RNA polymerase and topoisomerase I in M. 
smegmatis was further verified by reverse pull-down followed by immunoblotting (Figure 
3.4). In this assay, recombinant RNA polymerase beta’ subunit (N-terminal 6xHis) was 
used a bait to capture topoisomerase I from the M. smegmatis soluble cell lysate. The assay 
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confirmed a concentration dependent binding between the two proteins (lane 3-5 in Figure 
3.4). The combined results from Co-IP and Pull-down experiments confirmed the 
networking of topoisomerase I and RNAP with a novel mechanism that does not involve 
the zinc ribbon domains found in other bacterial topoisomerase I. 
  
 
 
 
Figure 3.5. M. tuberculosis H37Rv topoisomerase I and RNA polymerase are protein-
protein interaction partners.  M. tuberculosis RNA polymerase (RNAP) was detected by 
western blot using a monoclonal antibody against E. coli RNAP β subunit that cross-react 
with mycobacteria RNAP.  (A) Pull-down assay.  Lane 1: Total soluble lysate of M. 
tuberculosis H37Rv (10 µg).  Eluates from HisPur cobalt resin incubated with 250 µg of 
lysate and purified His-tagged MtbTopoI (lane 2), 6xHisMocr (lane 3) or without any His-
tagged protein (lane 4). (B) Co-Immunoprecipitation assay.  Lane 1: Total soluble lysate 
of M. tuberculosis H37Rv (10 µg).  Immunoprecipitates from 250 µg of total soluble 
lysates incubated with IgG against MtbTopoI (lanes 2,3), no IgG added (lane 4), IgG from 
pre-immune serum (lane 5) were analyzed by western blot with the antibody recognizing 
RNAP β subunit. 
 
 
RNAP-Topoisomerase I interactions are conserved in M. tuberculosis H37Rv 
M. smegmatis is a useful model system for the understanding of processes in 
pathogenic M. tuberculosis (Shiloh et al., 2010). The protein-protein interaction between 
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topoisomerase I and RNAP could be conserved among these mycobacteria. The RNAP-
topoisomerase I interaction in M. tuberculosis H37Rv was studied by Pull-down (Figure 
3.5, A), and Co-IP assays (Figure 3.5, B).  Results from both approaches (lane 2 in Figure 
3.5, A; lanes 2,3 in Figure 3.5, B) confirmed the conservation of RNAP-topoisomerase I 
interaction in M. tuberculosis.  
 
Direct physical interaction between Topoisomerase I and RNA polymerase beta’ 
subunit 
The results from the Co-IP and pull-down experiments indicate the presence of 
Mycobacteria topoisomerase I and RNAP in the same complex. However, a direct physical 
interaction between these two partners in the absence of DNA or other Mycobacteria 
proteins was not addressed. The direct protein-protein interactions were analyzed with 
purified recombinant proteins.  Physical interaction between the M. smegmatis RNA 
polymerase beta’ subunit and topoisomerase I was demonstrated by both co-
immunoprecipitation (Figure 3.6, A) and pull-down experiments (Figure 3.6, B).  This 
protein-protein interaction is specific.  No interaction with MsmTopoI could be observed 
for M. smegmatis RNA polymerase beta subunit (Figure 3.6, A).   E. coli topoisomerase I, 
with CTD that share no homology with MsmTopoI, also did not interact with M. smegmatis 
RNA polymerase beta’ subunit (Figure 3.6, C).  
 
Mapping of MsmTopoI sequence required for interaction with RNAP  
Pull-down (Figure 3.7, A) and Co-IP (Figure 3.7, B) assays were first conducted to 
verify that only the CTD (D5-D8, plus tail at C-terminal end), but not the NTD (D1-D4) 
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of MsmTopoI is involved in the protein-protein interaction with RNAP.  Pull-down assay 
with purified recombinant His-tagged proteins retaining different regions of the CTD of 
MsmTopoI as bait was then used to further identify sequence in MsmTopoI-CTD required 
for pull-down of RNAP (prey) from the soluble cell extract.  The pull-down of RNAP 
(prey) by protein-protein interaction could be observed only when the full-length 
MsmTopoI, or MsmTopoI-CTD was used as the bait (Figure 3.8, A; Lane 2,8). Equal molar 
amounts of the bait protein (subdomains of topoisomerase I) was used in these assays. 
MsmTopoI-909t (D1-D8) of topoisomerase I is only missing the tail at the C-terminal end 
(last 27 amino acids), but it still lacks affinity for RNAP. This data indicated that the 
protein-protein interaction with RNAP is mediated via the C-terminal tail sequence (amino 
acids 910-936) of MsmTopoI (Figure 3.8, B).    
 
Increased sensitivity to antibiotics and oxidative stress from overexpression of 
MsmTopoI-CTD  
Overexpression of the MsmTopoI-CTD is expected to inhibit the interaction 
between MsmTopoI and RNAP.  Following tetracycline-induced overexpression of 
recombinant MsmTopoI-CTD in M. smegmatis mc2 155 (Figure 3.9, A), less full length 
MsmTopoI was pulled down by His-tagged RNAP beta’ subunit (Figure 3.9, B).  The 
MsmTopoI-CTD overexpression did not affect the growth rate in 7H9 media (Figure 3.10).  
However, increased sensitivity to stress challenge from antibiotics (moxifloxacin, 
streptomycin) and hydrogen peroxide resulted from the MsmTopoI-CTD overexpression, 
as seen from the comparison of the diameters of zone of inhibition between the control 
strain and MsmTopo-CTD overexpressing strain (Figure 3.11, B).  Following treatment 
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with either moxifloxacin (0.5 µM, 1 µM) or hydrogen peroxide (10 mM, 20 mM), there 
was significantly greater loss of viability for the MsmTopoI-CTD overexpressing strain 
(Figure 3.11, A).  These results showed that inhibition of MsmTopoI-CTD protein-protein 
interactions can be correlated to enhanced sensitivity to antibiotics and oxidative stress. 
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Figure 3.6. Direct physical interaction between purified M. smegmatis topoisomerase I and RNA polymerase β' subunit.   
(A) Purified RNA polymerase β’ subunit (lanes 1-4) but not β subunit (lanes 6-9) can be co-immunoprecipitated with MsmTopoI.  
The co-immunoprecipitation reaction contained 100 (lanes 1, 6) or 200 nM of MsmTopo I (lanes 2, 7) along with 125 nM of β’ 
(lanes 1-4) or β (lanes 6-9) subunit of RNAP.  Lanes 3, 8: no MsmTopoI added.  Lanes 4, 9: no IgG added.  Lanes 5, 10: purified 
RNAP subunit (1.5 µg).  The proteins in the gel were stained with Coomassie blue following SDS PAGE.  M: Molecular weight 
standards. 
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Figure 3.6. Direct physical interaction between purified M. smegmatis topoisomerase I and RNA polymerase β' subunit  
(B) Pull-down assay with HisPur cobalt resin.  Lane 1: 25 ng of MsmTopoI. The pull-down reactions contained 15 nM of His-RNAP 
β’ subunit incubated with 5, 10, 20, 40, 60, 80 nM (lanes 2-7) of MsmTopoI.  Lane 8: control of 60 nM MsmTopoI with no RNAP 
β’ subunit added.   MsmTopoI pulled down by His-RNAP β’ subunit were visualized by western blot.  The nitrocellulose membrane 
was then stained with Ponceau S.  M: Protein molecular weight standards.  
(C) Pull-down assay for cross-interaction studies; Lanes 3, 4, 5 are loaded with eluates from the pull-down reactions of recombinant 
RNA polymerase b’ subunit. Lanes 6, 7, 8 represent the eluates from the pull-down with recombinant RNA polymerase b. 
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Figure 3.7. Identification of MsmTopoI domain required for interaction with RNAP.   
(A) M. smegmatis soluble lysate was incubated with the His-tagged recombinant MsmTopoI or its fragment, and the eluates from 
the reaction were analyzed by western bloting. TopoI-CTD but not TopoI-NTD can interact with RNAP in M. smegmatis cell lysate.  
(B) Direct physical interaction between TopoI-CTD and RNAP β’ subunit was verified by Co-IP assay. Purified RNAP β’ subunit 
was incubated with MsmTopoI or its fragment, and the proteins immunoprecipiated by TopoI antibodies from the reactions were 
analyzed by SDS-PAGE/Coomassie staining. The assay confirms a physical interaction of RNAP β’ with MsmTopoI-CTD (Lane 
6), and not MsmTopoI-NTD (Lane 5). Purified RNAP β’, by itself, did not bind with the antibody (Lane 7) or the beads (Lane 8). 
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Figure 3.8. Mapping of MsmTopoI sequence required for interaction with RNAP.  
(A) Pull-down assay with MsmTopoI truncation mutants lacking different segments of the TopoI-CTD.  M. smegmatis soluble lysate 
was incubated with different constructs of the recombinant MsmTopoI, and the eluates were probed for the presence of RNAP.  The 
full-length recombinant MsmTopoI (Lane 2), and CTD-MsmTopoI (Lane 8) can interact with RNAP.  
(B) Domain arrangement of MsmTopoI is shown here. The results from pull-down and Co-IP assays, taken together, demonstrate 
that the tail at the C-terminal end of MsmTopoI interacts with RNAP. 
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Figure 3.9. Inhibition of MsmTopoI-RNAP interaction by overexpression of recombinant MsmTopoI-CTD.   
(A) The tetracycline induced overexpression of MsmTopoI-CTD was confirmed by western blot analysis with rabbit polyclonal 
antibodies. Lane 1: Lysate (10 µg) of M. smegmatis transformed with control vector. Lane 2: Lysate (10 µg) of M. smegmatis 
transformed with pMsmTopoI-CTD.   
(B) Pull-down of MsmTopoI from M. smegmatis lysate by His-tagged RNAP β’ subunit is reduced by the competing, overexpressed 
MsmTopoI-CTD. Pull-down of MsmTopoI, and MsmtopoI-CTD from the lysate (350 µg) by His-RNAP β’ (5 nM or 10 nM) was 
analyzed by western blot. Lane 1, 3: Pull-down reactions with lysate from the strain transformed with the control vector (control) in 
the presence of 5 nM His-RNAP β’ or 10 nM His-RNAP β’. Lane 2, 4: Pull-down reactions with lysate from the strain overexpressing 
the MsmTopoI-CTD (CTD-OE) in the presence of 5 nM His-RNAP β’ or 10 nM His-RNAP β’. Lane 5, 6: The lysates from either 
the control strain or the overexpression strain were incubated with the beads, as a negative control for the pull-down assays. Lane 7: 
lysate (10 µg) from M. smegmatis transformed with the control vector. Lane 8: lysate (10 µg) from M. smegmatis overexpressing 
the MsmTopoI-CTD. The nitrocellulose membrane was later stained with Poneau S for the detection of the Bait (His-RNAP β’). 
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Figure 3.10. Effect of overexpressing the CTD of MsmTopoI on growth 
The effect of overexpressing the CTD of MsmTopoI in M. smegmatis (CTD-OE) on its growth was monitored by measuring the 
OD600 over a period of 2 days. The overexpression by itself did not have any effect on growth pattern, as evident from the growth 
curves of the untreated cultures of the control and the overexpression strain. However, treating the cultures with a sub-MIC 
concentration of Moxifloxacin (0.15 µM) has slowed down the growth of the overexpression strain. 
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Figure 3.11. Effect of TopoI-CTD overexpression on sensitivity of M. smegmatis to 
stress challenge.    
(A) Following treatment with moxifloxacin or hydrogen peroxide for 12 hours, the 
untreated and treated cultures of the vector control strain (control), and MsmTopoI CTD-
overexpression (CTD-OE) strain were serially diluted, and plated on LB-Agar. The viable 
colony counts (CFU/ml) were determined to calculate the relative survival ratios as the 
colony counts of the treated cultures divided by the colony counts of the untreated cultures. 
 (B) The tetracycline-induced cultures of the vector control strain (control), and the 
MsmTopo CTD-overexpression strain (CTD-OE) were spread on LB plates, and a blank 
paper disc was placed on the plate. 20 µl of the antibiotic or hydrogen peroxide was added 
to the disc. The plates were incubated at 37°C for 60 hours, and the zone of inhibition was 
measured.  Error bars represent the standard deviation (n=3). Student’s t-test was used to 
calculate the p-values (* p<0.05; ** p<0.005, ***p<0.0005).  
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Figure 3.12. The C-terminal tail of topoisomerase I from actinobacteria is rich in basic amino acids 
Topoisomerase I from different Actinobacteria were aligned using Constraint-based multiple alignment tool, COBALT 
(Papadopoulos & Agarwala, 2007). The regions of high conservation are highlighted. Mycobacterial topoisomerase I has a highly-
conserved region (AKKAAAK) in the tail. 
 
 
 
 
 
 
 104 
DISCUSSION 
TopoI is the only type IA topoisomerase encoded in the genomes of Mycobacteria, 
and has been shown to be essential for the viability of both M. tuberculosis (Ahmed et al., 
2014; Ravishankar et al., 2015) and M. smegmatis (Ahmed et al., 2015).  The identification 
of the protein-protein interaction partners of Mycobacteria TopoI is likely to provide 
insights into the in vivo functions and regulation of this potential antibacterial target.  It has 
been reported that the relaxation activity of MtbTopoI and MsmTopoI can be inhibited by 
interaction with a MazF homolog (Huang et al., 2010), as well as D-ribokinase (Yang et 
al., 2011).  The catalytic activity of MtbTopoI can also be modulated by interaction with 
the nucleoid associated protein HU (Ghosh et al., 2014).  These previously identified 
protein-protein interactions may be relevant for the regulation of Mycobacteria TopoI 
activity.  However, experimental data on protein-protein interactions of Mycobacteria 
TopoI that may inform on the physiological setting of its function is currently not available.  
In this study, we tried to identify such potential partners present in total soluble proteins of 
M. smegmatis with the approaches of Co-IP and pull-down assays coupled to mass 
spectrometry.  
RNA Polymerase was identified as a protein-protein interaction partner for 
MsmTopoI by both approaches.  A recent ChIP-Seq study showed that M. tuberculosis 
TopoI and gyrase are recruited to genomic loci with high transcriptional activity, and 
MtbTopoI was localized behind RNAP to be in position for relaxing the negative supercoils 
generated during transcription (Ahmed et al., 2017).  Our studies here demonstrated that 
M. tuberculosis RNAP can recruit TopoI via direct protein-protein interaction to facilitate 
the co-localization during transcription elongation. While protein-protein interaction with 
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the RNAP beta’ subunit has been previously reported for the CTD of E. coli TopoI (Cheng 
et al., 2003), it should be noted that the CTD of mycobacteria TopoI share no sequence and 
structural similarity with the CTD of bacteria outside the Actinobacteria phylum.  The CTD 
of E. coli TopoI are formed by zinc ribbon motifs stabilized by Zn(II) coordinated with 
four cysteines in each motif (D5-D7), or zinc ribbon like motifs of similar structures (D8-
D9).  Interaction sites for RNAP have been mapped to E. coli TopoI CTD regions of D5-
D7 as well as D8-D9 (Cheng et al., 2003).  Analysis of MsmTopoI protein sequence 
(Bhaduri et al., 1998) and determination of D1-D6 structure of MtbTopoI (Tan et al., 2016) 
have shown that the CTD of mycobacteria are formed by repeats of a distinctively different 
structural motif containing a beta sheet and alpha helix, with no Zn(II) present.  The results 
reported here demonstrate that while the different bacterial species have evolved to have 
distinct sequence and structures of CTD in TopoI potentially through acquiring different 
duplicated gene segments during evolution, the protein-protein interaction with the beta’ 
subunit of RNAP has simultaneously co-evolved through divergent mechanisms in 
different bacterial phylum.   
Molecular simulations predicted that salt bridges and hydrogen bonds formed by 
basic residues positioned over a large molecular surface formed by the zinc ribbon motifs 
of E. coli TopoI are responsible for interactions with acidic residues in RNAP (Tiwari et 
al., 2016). In contrast, a novel mechanism utilizing a short stretch of C-terminal tail is 
employed instead for the TopoI-RNAP interaction in bacteria that do not have Zn(II) 
binding TopoI-CTD.  As shown in Figure 3.12, the amino acid sequence of the C-terminal 
tail is highly conserved in mycobacteria TopoI sequence and rich in basic residues.  The 
basic region represented by the C-terminal tail of MsmTopoI and MtbTopoI has been 
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proposed to participate in the binding of DNA to promote strand passage during catalysis 
(Ahmed et al., 2013).  Direct interaction of the C-terminal tail with RNAP would facilitate 
the rewinding of single-stranded DNA following their exit from the RNAP elongation 
complex to prevent to prevent stabilization of R-loop structure and inhibition of 
transcription elongation.  The TopoI-RNAP interaction may be especially important for 
efficient transcription response to stress conditions to achieve maximal survival following 
antibiotic or oxidative challenge.  Competition for RNAP interaction by overexpressed 
recombinant MsmTopoI-CTD may have contributed to the increase in sensitivity to 
antibiotics and oxidative stress challenge observed here.  Nevertheless, we cannot rule out 
that other protein-protein interactions inhibited by overexpressed MsmTopo-CTD may 
also contribute to the increased sensitivity.  Other potential protein-protein interaction 
partners identified in our Co-IP and pull down experiments are currently being investigated 
in further studies.   
TopoI is the only type IA topoisomerase in mycobacteria.  Based on the essentiality 
of TopoI for the viability of M. tuberculosis, MtbTopoI is deemed as a validated target for 
discovery of novel TB drugs (Ravishankar et al., 2015; Nagaraja et al., 2017).  Due to its 
involvement in transcription response to stress challenge, mycobacteria TopoI inhibitors 
could be especially useful in combination with other antibiotics. 
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CHAPTER 4 
INVESTIGATING A DIRECT INTERACTION BETWEEN ESCHERICHIA COLI 
TOPOISOMERASE I AND RECA 
 
ABSTRACT 
 Protein-protein interactions are of special importance in cellular processes, 
including replication, transcription, recombination, and repair. Escherichia coli 
topoisomerase I (EcTopoI) is primarily involved in the relaxation of negative DNA 
supercoiling. E. coli RecA, the key protein for homologous recombination and SOS DNA-
damage response, has been shown to stimulate the relaxation activity of EcTopoI. The 
evidence for their direct protein-protein interaction has not been previously established. 
We report here the direct physical interaction between E. coli RecA and topoisomerase I. 
We demonstrated the RecA-topoisomerase I interaction via pull-down assays, and surface 
plasmon resonance measurements. Molecular docking supports the observation that the 
interaction involves the topoisomerase I N-terminal domains that form the active site. Our 
results from pull-down assays showed that ATP, although not required, enhances the 
RecA-EcTopoI interaction. We propose that E. coli RecA physically interacts with 
topoisomerase I to modulate the chromosomal DNA supercoiling. 
 
INTRODUCTION 
Protein-protein interactions (PPIs) are essential features of almost every cellular 
process (Coulombe et al., 2004; Perkins et al., 2010). Genomic processes including DNA 
replication, transcription, translation, recombination, and repair require an ensemble of 
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proteins (Coulombe et al., 2004). PPIs, especially transient protein interactions, are vital in 
the regulation of the above-mentioned genomic processes (Perkins et al., 2010; Ngounou 
Wetie et al., 2013). Proteins involved in transient interactions can function as independent 
units in the cells, and certain post-translational modifications on these proteins or binding 
of ligands can trigger the protein interactions. A protein’s function is defined and controlled 
through interaction with other proteins, or biomolecules (Ngounou Wetie et al., 2013).  
Understanding protein-protein interaction network in Escherichia coli would be 
essential in broadening current insight on the fundamental cellular processes. PPIs involved 
in DNA damage response would be important for the development of antibiotic resistance 
(Marceau et al., 2013). We are reporting here a direct physical interaction of RecA, the key 
player of homologous recombination and SOS DNA-damage response in E. coli, with 
DNA topoisomerase I. RecA family of recombinases, conserved in most of the bacteria, 
are ATP-dependent proteins mediating homologous recombination, DNA repair and 
genome integrity (Karlin and Brocchieri, 1996; Lin et al., 2006; Cox, 2007). Homolog 
searches have provided evidence for conservation of RecA in bacteria, archaea, and 
eukaryotes, although, the functions of the homologs have diversified with evolution. Most 
of the archaeal species have two RecA homologs (RadA and RadB), whereas the 
eukaryotes have multiple representatives of the RecA family (Rad51, Rad51B, Rad51C 
Rad51D, Dmc1, XRCC2, XRCC3, and RecA) (Lin et al., 2006). RecA monomers bind to 
single-stranded DNA (ssDNA) in an ATP-dependent manner forming an active 
nucleoprotein filament (McGrew and Knight, 2003; Bell, 2005). E. coli RecA, a prototype 
of RecA family of proteins, has multiple roles in the cell. RecA catalyzes the DNA strand 
exchange mechanism by coupling with ATP hydrolysis, promoting the recombination 
 109 
process (Howard-Flanders et al., 1984; Cox, 1999; Cox, 2002; Lusetti and Cox, 2002; Cox, 
2003). RecA can also function as a coprotease of LexA, and UmuD proteins. RecA 
facilitates the autocatalytic cleavage of LexA repressor, which is required for inducing the 
SOS response (Little, 1991; Harmon et al., 1996). It can also facilitate the autocatalytic 
cleavage of UmuD to an active UmuD’, which is a component of a low fidelity DNA 
polymerase V that is involved in the translesion DNA synthesis (Patel et al., 2010).   
The topology of DNA is maintained by an important group of evolutionarily 
conserved enzymes called topoisomerases (Wang, 2002). The essential genomic processes 
such as replication, transcription, recombination, and repair can create topological strain or 
entanglement on the double helix of DNA (Vos et al., 2011). Topoisomerases transiently 
cleave and rejoin DNA (Wang, 1971) to resolve the topological strain or entanglement, and 
maintain the genomic stability (reviewed in (Wang, 1971; Berger, 1998; Champoux, 2001; 
Chen et al., 2013)).   
E. coli DNA topoisomerase I is primarily involved in the relaxation of negatively 
supercoiled DNA by the stand passage mechanism (Brown and Cozzarelli, 1981; Tse-Dinh, 
1986; Champoux, 2002b). It has an important function in preventing excess negative 
supercoiling of DNA (Drlica, 1992)  which can affect global transcription and result in 
growth inhibition. According to a previous report, the relaxation activity of E. coli 
topoisomerase I is stimulated by RecA; suggesting a functional interaction between RecA 
and topoisomerase I (Reckinger et al., 2007). It remains unclear whether this stimulatory 
effect is due to a direct protein-protein interaction between E. coli RecA and topoisomerase 
I, or is only due to the effect of E. coli RecA on DNA conformation. More recent results 
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showed that mutations in E. coli topA gene coding for topoisomerase I can diminish the E. 
coli SOS response to DNA damage and antibiotics treatment (Yang et al., 2015). 
 
Figure 4. 1. Multiple activities of E. coli RecA (Cox, 2007) 
 
The interaction between RecA and topoisomerase I may influence the increase in 
antibiotic resistance (Hastings et al., 2004; Beaber et al., 2004; Thi et al., 2011) and 
persistence shown to be associated with the SOS response (Dörr et al., 2009). In this study, 
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we tested the hypothesis that E. coli RecA might physically interact with topoisomerase I 
to modulate the topoisomerase I catalytic activity and DNA supercoiling.  
Herein, we present evidence for a direct physical interaction between E. coli RecA, 
and topoisomerase I in solution by pull-down assays (Yang et al., 2015) as well assess the 
influence of ATP, and the domains of topoisomerase I involved in the protein-protein 
interaction with RecA. We further investigated the inter-protein interaction between E. coli 
RecA and topoisomerase I by using surface plasmon resonance (SPR) and molecular 
docking. SPR is a widely accepted label-free biophysical tool in order to investigate 
biomolecular interactions (Wilson, 2002; Willander & Al-Hilli, 2009; Tiwari et al., 2014), 
including PPIs (Berggård et al., 2007; Tiwari et al., 2015), whereas molecular docking can 
be used to provide structural insights for PPIs (Smith and Sternberg, 2002; Gray et al., 
2003). The structural basis for the protein-protein interaction was predicted by molecular 
docking that shows the N-terminal domains (NTD) of topoisomerase I are involved in the 
interaction with RecA. The NTD (D1-D4, amino acids 1-597) contain the active site for 
DNA cleavage-religation (Lima et al., 1994).  Experimental evidence supporting this 
prediction was provided from pull-down assays.  
MATERIALS AND METHODS 
Bacterial strains and plasmids 
E. coli strain BW25113 (Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-
1, Δ(rhaD-rhaB)568, hsdR514), obtained from Yale CGSC (Datsenko and Wanner, 2000), 
was used for preparing the cell lysate used in the pull-down of RecA from total cellular 
proteins.  Plasmid, pLIC-ETOP was used for the expression and purification of 
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recombinant E. coli topoisomerase I with 6x-His tag (Sorokin et al., 2008).  A plasmid, 
pLIC-NTD-ETOP was constructed similarly as pLIC-ETOP by introducing the coding 
sequence of NTD of E. coli topoisomerase I (amino acids 1-597) into a pLIC-HK cloning 
vector that allows T7 RNA polymerase-dependent expression of His-tagged NTD of 
topoisomerase I for purification (Sorokin et al., 2008).  A pET His6-Mocr TEV cloning 
vector (2O-T) (gift of Scott Gradia, Addgene #29710) was used for expression and 
purification of a recombinant viral protein, His-Mocr (DelProposto et al., 2009), that was 
used as negative control in the pull-down assays.  
 
Purified Proteins 
E. coli topoisomerase I with a N-terminus 6x-Histidine tag (His-EcTopoI) was 
expressed from pLIC-ETOP in E. coli BL21-AI by induction with 1 mM IPTG, 0.02% L-
Arabinose as described previously (Sorokin et al., 2008). N-terminal domains (D1-D4) of 
the E. coli topoisomerase I with a N-terminus 6x-Histidine tag (His-NTD-EcTopoI) was 
expressed from pLIC-NTD-ETOP in BL21 Star (DE3) by induction with 1 mM IPTG.  
Expression of recombinant His-tagged Mocr was induced in BL21 star (DE3) with 1 mM 
IPTG. Ni- Sepharose 6 Fast Flow beads (GE Healthcare Life Sciences) were used to purify 
these proteins by affinity chromatography (Cheung et al., 2012) to near homogeneity as 
described previously (Sorokin et al., 2008) with some modifications. Purified E. coli RecA 
was purchased from New England BioLab for use in assays involving verification of direct 
protein-protein interactions with topoisomerase I.  
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Figure 4.2. Purification of His-tagged E. coli topoisomerase I and its NTD:  
(A) Purification of EcTopoI, Lane1: Protein color ladder, Lane 2-10: Eluates from the 
single stranded DNA cellulose column. (B) Purification of NTD-EcTopoI, Lane 1: Protein 
color ladder, Lane 2-10:  Eluates from the Ni-Sepharose 6 fast flow column.  
 
Recombinant EcTopoI with N-terminus 6xHis tag (His-EcTopoI) was expressed 
from exponential phase BL21-AI competent cells by induction with 1 mM IPTG, and 
0.02% L-Arabinose. The soluble protein fraction obtained from lysing the cells was 
incubated with Ni-NTA agarose beads (Qiagen), and packed into a column after a few 
washes with PBS buffer (50 mM sodium phosphate, 300 mM sodium chloride; pH 8.0) 
containing 10 mM imidazole. To achieve maximum purity, further washes were carried 
out with PBS buffer containing 20mM Imidazole for at least 100 column volumes. The 
recombinant 6x-Histidine tagged EcTopoI was then eluted with 250mM Imidazole. The 
eluted recombinant protein was dialyzed to remove Imidazole, and passed through a single 
stranded DNA cellulose column, as described previously (Zhu & Tse-Dinh, 1999) (Figure 
4.2, A). The recombinant NTD-topoisomerase I (NTD EcTOP1) was expressed from BL21 
Star (DE3) cells by induction with 1mM IPTG at exponential growth phase. The 
purification protocol followed was similar to the protocol for recombinant EcTopoI 
purification, except here the soluble protein fraction was passed through a single column: 
Ni- sepharose 6 fast flow column (GE Healthcare) (Figure 4.2, B).  
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Pull-down assays to study direct physical interactions between purified proteins 
Pull-down assays were carried out to establish the physical interactions of proteins 
in solution (Yang et al., 2015). An assay involving the incubation of purified RecA and 
topoisomerase I was carried out to study the direct physical interactions between these 
proteins. Purified His-EcTopoI serves as bait in these assays. Individual pull-down 
reactions were set up by incubating constant amount of bait (10 nM) with varying 
concentrations (0-80 nM) of RecA (prey) for 2 hours at 4°C. The bait-prey interactions 
were set up in pull-down buffer (10 mM HEPES, pH 7.4, 100 mM NaCl, 0.5 mM MgCl2, 
0.005% v/v Tween-20). The HisPur Cobalt Agarose resin (Thermofisher), previously 
equilibrated in the above-mentioned pull-down buffer, was mixed with the bait-prey 
reaction. Following an overnight incubation at 4°C, the reactions were centrifuged and the 
supernatant was discarded. The resin pellet was then washed three times in HEPES buffer, 
and the proteins bound to the resin were eluted with pull-down buffer containing 400 mM 
imidazole. The eluates were electrophoresed in a polyacrylamide SDS gel, and RecA was 
detected by western blotting (Burnette, 1981) with Anti-RecA monoclonal antibody (MBL 
International Corp.). A C-DiGit blot scanner (LI-COR) was used to detect the 
chemiluminescent western blot signal, and the signal intensity was quantified (Image 
Studio Digits version 4.0). 
A comparative study was performed to compare the RecA-topoisomerase I binding 
efficiency in the presence, and absence of 5 mM ATP. The assay was carried out with a 
constant amount (10 nM) of His-EcTopoI as bait, and varying concentrations (0-80 nM) of 
RecA as prey.  An independent similar assay was carried out with a constant amount (10 
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nM) of NTD-EcTopoI as bait, and varying RecA concentrations (0-60 nM) as prey in the 
presence of ATP. 
  
Pull-down assays on E. coli soluble cell lysate  
In this assay, E. coli strain (BW25113) cultured in LB medium for 16 hours to 
stationary phase (OD600=2.5), and the culture was pelleted. The cell pellet was suspended 
in the pull-down buffer containing 1mg/ml lysozyme. The suspended cells were subjected 
to lysis by four freeze-thaw cycles. The lysate was centrifuged at 13000xg for 2 hours at 
4°C. The soluble protein fraction was incubated with HisPur Cobalt Agarose resin 
(precleared) before its use in the pull-down reaction. The preclearing minimizes non-
specific binding of proteins to the beads. Either full length purified EcTopoI or NTD-
EcTopoI was used as bait. A Bacteriophage T7 protein, Mocr, with a N-terminus 6x-His 
tag was used as bait in the negative control for the pull-down assay (DelProposto et al., 
2009).  
Bait (40 nM), and precleared soluble protein fraction (150 µg) were incubated at 
4°C for 2 hours. HisPur Cobalt Agarose resin (Thermofisher) was added to the reaction, 
and incubated overnight at 4°C. On the following day, the resin-reaction mixture was spun, 
and the supernatant was discarded. The bead pellet was washed three times in pull-down 
buffer with 10 mM imidazole to minimize non-specific binding of histidine rich proteins 
to the resin. The proteins bound to the resin were finally eluted in 400 mM imidazole, and 
the eluates were subjected to SDS-PAGE analysis. A western blot was performed to probe 
for RNA polymerase, and RecA in the eluates using a monoclonal antibody against RNA 
polymerase beta (BioLegend), and RecA respectively. 
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Surface Plasmon Resonance (SPR) 
Biacore T200 SPR instrument was used to record SPR sensorgrams. EcTopoI was 
immobilized onto CM5 sensor surface using standard amine coupling chemistry. Buffered 
solutions with various concentrations of RecA were flown over EcTopoI immobilized 
sensor surface. EcTopoI in 10 mM sodium acetate buffer (pH 5.5) was immobilized onto 
a CM5 chip surface via standard amine-coupling chemistry. 1XHBS-P+ (10 M HEPES, 
pH 7.4, 150 mM NaCl, 0.05% surfactant P-20) was used as the immobilization running 
buffer. The remaining surface reactive ester groups were quenched using 1M 
Ethanolamine-HCl for 720 seconds. Buffered solutions of RecA protein (10 mM Tris-HCl; 
pH 7.5, 0.1 mM EDTA, 1 mM DTT, 10 mM MgCl2, 0.005% Tween-20 and 5% glycerol) 
at various concentrations were injected over EcTopoI saturated surface in the presence of 
RecA buffer. 1M NaCl was used to regenerate the sensor surface. The flow rate was 
maintained at 50 µL/min during the binding experiments and the data was collected at the 
rate of 10 Hz. All the experiments were carried out at 25oC.  
 
Molecular docking 
 The formation of inter-protein complex between EcTopoI and RecA was optimized 
using pyDockWEB (Jiménez-García et al., 2013). Protein coordinates from PDB entries 
4RUL (full length EcTopoI, (Tan et al., 2015)) and 2REB (E. coli RecA, (Story et al., 
1992)) were used in the docking study as receptor (EcTopoI) and ligand (RecA), 
respectively. The top ten docked complexes from the pyDockWEB outputs, based on 
energy scoring, were used to predict the RecA interaction site on EcTopoI. The output PDB 
file of the top scored complex was analyzed using PDBsum database (Laskowski et al., 
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1997; Laskowski, 2001). Chimera molecular graphics software (Pettersen et al., 2004) was 
used to visualize the structure and to generate images of the docked complexes. 
RESULTS 
Pull-down assay demonstrates a direct physical interaction between E. coli RecA and 
topoisomerase I  
A functional association between E. coli RecA and topoisomerase I have been 
reported previously (Cunningham et al. 1981; Reckinger et al., 2007). More recently, a role 
of topoisomerase I was observed in E. coli SOS response (Liu et al., 2011; Yang et al., 
2015), which prompted us to verify the possibility of a direct physical interaction between 
these proteins. Purified His-EcTopoI and RecA were incubated together in the presence of 
ATP, and pulled-down with Cobalt agarose resin. The amount of RecA bound to EcTopoI 
was determined by western blot analysis of the eluates from the reaction with monoclonal 
antibodies against RecA. The results (Fig. 4.3) confirmed the possibility of a direct 
interaction between these proteins. Pull-down of RecA by the resin required the presence 
of His-EcTopoI. Both E. coli RecA, and topoisomerase I bind strongly to single-stranded 
DNA. However, according to this pull-down result with purified RecA and topoisomerase 
I, the association between these proteins does not require the presence of DNA.  
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Figure 4.3. Direct physical interaction between purified E. coli RecA and 
topoisomerase I (A) Pull-down scheme (B) Pull-down of E. coli RecA by topoisomerase 
I at an increasing RecA: EcTopoI molar ratios, as measured by western blot using 
antibodies against RecA. Lanes 1-4: Eluates from pull-down reactions with increasing 
RecA: EcTopoI molar ratios. Lane 5: Negative control in the absence of EcTopoI. (C) 
Graph showing average values (symbols) of RecA band intensities, from three independent 
experiments, relative to the maximal intensity of RecA in the pull-down reactions. The 
error bars represent standard deviations of three measurements. 
 
Influence of ATP on the binding efficiency of RecA with EcTopoI  
The functional interactions between E. coli RecA and topoisomerase I were 
observed in the presence of ATP.  According to a previous report (Konola et al., 1994), 
ATP binds to the P-loop of RecA.  E. coli RecA undergoes ATP dependent conformational 
change (Cox, 2003) that could affect its interaction with topoisomerase I (Cunningham et 
al. 1981; Reckinger et al., 2007). We, therefore tested the influence of ATP on the physical 
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interaction between E. coli RecA and topoisomerase I with pull-down reactions in the 
absence or presence of ATP.  
While the results from the pull-down assay suggested that the protein-protein 
interaction between E. coli RecA and topoisomerase I may not require ATP, the presence 
of ATP in the pull-down assay was found to enhance the protein-protein interaction 
significantly (Fig.4.4, A; 4.4, B).  Experimental data from one trial of pull-down 
experiment is shown here (Fig.4.4, A). Similar enhancement of the interaction by the 
presence of ATP were seen in two additional trials of the experiment (Fig. 4.4, C). 
However, ATP did not appear to be absolutely required for the interaction. Direct protein 
interaction between E. coli RecA and topoisomerase I in the absence of ATP has been 
confirmed by surface plasmon resonance (SPR) measurements (Fig. 4.4, D; 4.4, E). We 
could not obtain meaningful SPR sensorgrams for RecA-EcTopoI interactions in the 
presence of ATP due to technical difficulties. Fig. 4.4, D depicts the SPR sensorgrams for 
RecA binding to EcTopoI at various RecA (analyte) concentrations. The sensorgrams for 
each concentration represent the triplets. The SPR sensorgrams were evaluated using 
Biaevaluation software version 2.0 via 1:1 kinetics binding analysis (Wang et al., 2012). 
Since the signals for RecA-EcTOP1 complex dissociation were relatively slower, the 
dissociation rate constant (kd) value was determined by fitting the highest analyte 
concentration data (Fig. 4.4, E), with dissociation signals recorded for longer time as 
compared to lower concentrations.  The association rate constant (ka) was determined by 
fitting the full set of sensorgrams. The equilibrium dissociation constant (KD=kd/ka), for 
the direct binding of RecA with EcTopoI was determined to be ~1500 nM in the absence 
of ATP. The RecA-EcTOP1 binding experiments were also conducted in the presence of 
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ATP in the RecA solution (analyte mixture). However, the strong binding of the analyte 
mixture in the reference flow cell hindered meaningful SPR sensorgrams. 
 
Molecular docking results for the complex formation between RecA and EcTopoI  
 Fig. 4.5 depicts the binding complex, as predicted by pyDockWEB, between 
EcTopoI (receptor) and RecA (ligand). Fig. 4.5, A shows the surface representation for the 
binding of EcTopoI (green) and with RecA (10 different colors, except green, representing 
the RecA conformations upon binding with EcTopoI). Fig. 4.5, B shows the cartoon 
representation for the top-scored EcTopoI-RecA docked complex as well as the interacting 
amino acid residues, as predicted by PDBsum, across the binding interface. The amino acid 
residues predicted to be responsible for the formation of hydrogen bonds and salt bridges 
are listed in the tables 4.T1, 4.T2.  
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Fig. 4.4. ATP promotes binding of E. coli RecA to topoisomerase I.  (A) Comparative 
analysis of ATP’s influence on the direct protein interactions between RecA, and EcTopoI. 
Lanes 2-5: Eluates from pull-down reactions in the presence of 5 mM ATP. Lanes 6-9: 
Eluates of pull down reactions devoid of ATP. Lane 1: negative control (No EcTopoI (bait) 
in the reaction). (B) The quantified RecA band intensities. (C) Results from repeated trials 
of pull-down assays showing the influence of ATP on RecA-EcTopoI complex formation. 
(D) SPR sensorgrams for RecA binding to immobilized EcTopoI (E) SPR sensorgrams for 
RecA binding binding at 4000 nM RecA concentration with dissociation signals recorded 
for a longer time as compared to lower RecA concentrations. The sensorgrams for each 
concentration were recorded in triplets. The SPR sensorgrams were fitted to 1:1 kinetics 
binding model using Biaevaluation software version 2.0. The red colored lines are the fits. 
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Figure 4.5. RecA-EcTopoI complex predicted by molecular docking: (A) Green colored surface represents EcTopoI with light 
green as its C-terminal domain (CTD) and dark green as N-terminal domain (NTD). The surfaces in the other colors represent ten 
different predicted RecA conformations when it binds to EcTopoI, all with NTD of EcTopoI as the binding domain interacting with 
RecA. (B) Cartoon representation of the top scored docked RecA- EcTopoI complex. EcTopoI is shown in green color and RecA in 
blue color.  The amino acid residues across the EcTopoI-RecA binding interface that form hydrogen bonds and salt bridges are 
shown in sticks representation (orange colored sticks for EcTopoI and magenta colored sticks for RecA). 
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Amino acid residues predicted to be involved in the formation of hydrogen bonds and 
salt bridges: 
 The potential amino acid residues for the formation of hydrogen bonds and salt 
bridges, as predicted by PDBsum, across the binding interface of EcTopoI-RecA complex 
are listed in Table 4. T1 and 4. T2, respectively.  
 
Table 4. T1. Potential amino acid residues for the formation of hydrogen bonds during 
EcTopoI-RecA complex formation. 
 
EcTopoI RecA 
GLU (156) ARG (226) 
HIS (556) LEU (29) 
HIS (566) LYS (6) 
 
 
Table 4. T2. Potential amino acid residues for the formation of salt bridges during 
EcTopoI-RecA complex formation. 
 
EcTopoI RecA 
GLU (125) LYS (216) 
GLU (156) ARG (226) 
GLU (156) LYS (245) 
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Pull-down assay for complex formation between NTD-EcTopoI and RecA 
Molecular docking results have suggested that the NTD of EcTopoI can interact 
with RecA in E. coli. The possibility of the direct interaction of RecA with the NTD-
EcTopoI was verified by pull-down assays, involving the direct incubation of purified 
recombinant NTD-EcTopoI and RecA, in the presence of ATP. In these assays, NTD-
EcTopoI (bait) and RecA (prey) were incubated with HisPur Cobalt agarose resin, in the 
presence of ATP. The eluates from the pull-down reactions were analyzed by western 
blotting with monoclonal RecA antibodies. The results from the assay suggest that the N-
terminal domain of topoisomerase I and RecA can interact physically (Fig. 4.6). 
 
 
Figure 4.6. NTD of EcTopoI can interact with RecA as efficiently as full-length 
EcTopoI. (A) Pull-down of RecA, at an increasing RecA: NTD-EcTopoI molar ratios, as 
measured by western blot using antibodies against RecA. Lane 1-4: Eluates from the pull-
down reactions of increasing RecA (prey) to NTD-EcTopoI (bait) in the presence of ATP. 
Lane 5: negative control for the assay (The reaction has beads incubated with prey, in the 
absence of bait). Lane 6, 7: Eluates from reaction carried out with full-length EcTopoI, as 
bait. (B) Quantified RecA band intensities relative to the band intensity observed with pull-
down reaction corresponding to 1: 6 molar ratios of EcTopoI and RecA in lane 7 of Fig. 
4.6, A. The average values of three trials are shown here and the error bars represent the 
standard deviations.  
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Pull-down of RecA from E. coli soluble cell lysate by recombinant EcTopoI and NTD-
EcTopoI 
E. coli RecA has a stimulatory effect on the topoisomerase I relaxation activity, 
suggesting a possible protein-protein interaction between RecA and topoisomerase I 
(Reckinger et al., 2007). A direct physical interaction between RecA and EcTopoI with 
purified proteins in solution was verified (Fig 4.3). A pull-down assay using the E. coli cell 
lysate was performed to further confirm the interaction of E. coli topoisomerase I-NTD 
with E. coli RecA. The cell lysate, and His-EcTopoI or His-NTD-EcTopoI were incubated 
together with HisPur Cobalt agarose beads that have high affinity for the 6x-Histidine tag. 
The complexes recovered from the beads after the pull-down protocol were resolved by 
SDS-PAGE, and analyzed by western blot. The nitrocellulose membrane was probed for 
RecA and RNA polymerase with monoclonal antibodies against RecA and RNA 
polymerase beta subunit respectively.  
EcTopoI is known to interact with E. coli RNA polymerase via its CTD (Cheng et 
al., 2003). The results showed that both RecA, and RNA polymerase were pulled down by 
full-length topoisomerase I as expected (Fig. 4.7, lane 2). The data also confirmed that the 
NTD of topoisomerase I can interact with RecA in the cell lysate (Fig. 4.7, lane 3). 
Interaction between NTD-EcTopoI and RNA polymerase was not observed, demonstrating 
the domain specific interactions between EcTopoI and its partners (Cheng et al., 2003).  
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Fig. 4.7 Pull-down of RecA from E. coli cell lysates by EcTopoI and NTD-EcTopoI. 
Lane 2 and 3 represent the eluates from the pull-down reactions containing His-EcTopoI, 
His-NTD-EcTopoI as bait respectively. Lane 1, representing the eluate from the pull-down 
reaction with Mocr as bait, serves as a negative control. 
 
 
DISCUSSION 
In a previous study (Reckinger et al., 2007), the stimulation of topoisomerase I 
relaxation activity by E. coli RecA was seen only for topoisomerase I protein from E. coli 
and not for the topoisomerase I proteins from other species. This indicated that the 
stimulation of relaxation activity by RecA was not entirely due to the effect of RecA on 
DNA conformation.  Even though, previous studies suggested that E. coli RecA may 
stimulate topoisomerase I relaxation activity via direct protein-protein interaction, data to 
support such interaction was not available (Reckinger et al., 2007). We have presented 
evidence, here, for the first time to confirm a direct physical interaction between E. coli 
RecA and topoisomerase I. The presence of DNA was not required for this interaction.  
ATP, although not absolutely required, can enhance the protein-protein interaction between 
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E. coli RecA and topoisomerase I.  E. coli topoisomerase I plays an important role in the 
regulation of local and global DNA supercoiling (Liu and Wang, 1987; Drlica, 1992). The 
stimulation of topoisomerase I relaxation activity by RecA via direct protein-protein 
interaction allows RecA to add modulation of DNA supercoiling to its multiple roles.  This 
stimulation of topoisomerase I relaxation activity by RecA may enable relaxation-
dependent E. coli promoters to have higher transcription activities following DNA damage 
(Reckinger et al., 2007).   
As a type IA DNA topoisomerase, EcTopoI binds to the single-stranded region of 
negatively supercoiled DNA to initiate its relaxation activity (Champoux, 2001). The active 
site of EcTopoI (Tyr-319 nucleophile), responsible for single-stranded DNA cleavage and 
religation, is located in its NTD. The active site region formed an interface between the 
subdomains that enclose the toroid hole in its structure (Lima et al., 1994; Berger, 1998). 
Molecular docking and pull-down results reported here has provided evidence for a 
physical interaction of RecA with the NTD of topoisomerase I. The protein-protein 
interactions may either facilitate the loading of negatively supercoiled DNA onto 
topoisomerase I, or increase the catalytic rate of DNA relaxation by inducing 
conformational change in topoisomerase I. It is notable that EcTopoI interacts with RNA 
polymerase via its CTD (Cheng et al., 2003), so that the transcription-driven negative 
supercoiling can be relaxed efficiently to prevent hyper-negative supercoiling of DNA and 
suppress R-loop stabilization (Tan et al., 2015). Interaction with RecA takes place via a 
different domain in topoisomerase I and may also have functional significance in the 
physiological response of E. coli to DNA damage and antibiotic stress. Future studies will 
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further investigate the mechanism of the RecA-topoisomerase I interaction, and the 
physiological consequence of perturbation of this specific protein-protein interaction.   
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SUMMARY AND FUTURE WORK 
 
Communication between proteins is vital for essential cellular processes like transcription, 
replication, recombination and DNA repair. Understanding the network of a protein can 
provide insights into its functions in a physiological setting. The goal of my work is to 
identify novel protein partners of bacterial topoisomerase I, and explore the molecular 
mechanisms for interaction. Bacterial topoisomerase I, a type IA topoisomerase, is 
involved in resolving the hyper negative supercoiling of DNA in bacteria. The physical 
and functional association of the CTD of topoisomerase I with RNAP beta’ subunit in E. 
coli was previously reported. However, the molecular mechanism of interaction between 
these proteins was unknown. In chapter 1, the molecular mechanism of interaction between 
E. coli RNA polymerase and topoisomerase I was explored, and the findings were reported.  
The computation modeling (molecular docking, MD simulations) and pull-down 
experiments have identified key amino residues of EcTopoI involved in the salt-bridging 
and hydrogen bonding with RNAP. According to these studies, Lysine 664 and 627 of 
EcTopoI are essential for the formation and stabilization of the complex. It will be 
interesting to study the in vivo effects of mutating the Lysine residues (627, 664) of 
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EcTopoI. Currently, a mutant E. coli strain is under construction in Dr. Marc Drolet’s lab 
(University of Montreal). 
In chapter 2, novel protein partners of mycobacterial topoisomerase I were 
explored. Pull-down and Co-Immunoprecipitation assays (Co-IP) coupled to mass 
spectrometry were used to identify the protein network of mycobacterial topoisomerase I, 
MsmTopoI. RNAP and Putative helicases were identified as partners of MsmTopoI.  The 
putative helicase will be characterized, in the future, for its helicase activity. According to 
the preliminary data, the putative DEAD/DEAH Box helicase is a partial 3’-5’ DNA 
helicase. However, its RNA helicase activity should be verified. The mechanism of RNAP-
topoisomerase I interaction in mycobacteria was investigated and reported in chapter 3. 
Unlike in E. coli, a novel mechanism of interaction with RNAP beta’ subunit through the 
C-terminal tail of mycobacterial topoisomerase I was identified. The physiological 
relevance of the RNAP-topoisomerase I interaction during antibiotic and oxidative stress 
was also reported. 
The evidence for a direct physical interaction between the N-terminal domain of 
topoisomerase I, and RecA was reported in chapter 4. The physical interaction does not 
require DNA or ATP, although it was observed that ATP can improve the interaction 
efficiency. In the future, it will be essential to study the molecular mechanisms of RecA-
topoisomerase I interaction in E. coli. In addition, the cellular response of perturbing RecA-
topoisomerase I association should be studied. 
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